The synthesis of a series of adenosine A3 receptor agonists by Broadley, Kenneth John et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/91685/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Broadley, Kenneth John, Burnell, Erica, Davies, Robin H., Lee, Alan T. L., Snee, Stephen and
Thomas, Eric J. 2016. The synthesis of a series of adenosine A3 receptor agonists. Organic &
Biomolecular Chemistry 14 (15) , pp. 3765-3781. 10.1039/C6OB00244G Item availability restricted.
file 
Publishers page: http://dx.doi.org/10.1039/C6OB00244G <http://dx.doi.org/10.1039/C6OB00244G>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
ARTICLE 
 
 The synthesis of a series of adenosine A3 receptor 
agonists 
Kenneth J. Broadley,a Erica Burnell,b Robin H. Davies, †c Alan T. L. Lee,b 
Stephen Sneeb and Eric J. Thomasb*  
A series of 1-(6-aminopurin-9-yl)-1-deoxy-N-methyl--D-ribofuranuronamides characterised by 
2-dialkylamino-7-methyloxazolo[4,5-b]pyridin-5-ylmethyl substituents on N6 of interest for 
screening as selective adenosine A3 receptor agonists, have been synthesised.  This work involved 
the synthesis of 2-dialkylamino-5-aminomethyl-7-methyloxazolo[4,5-b]pyridines and analogues 
that were coupled with the known 1-(6-chloropurin-9-yl)-1-deoxy-N-methyl--D-ribofuranuronamide. 
The oxazolo[4,5-b]pyridines were synthesized by regioselective functionalisation of 2,4-
dimethylpyridine N-oxides. The regioselectivities of these reactions were found to depend upon the 
nature of the heterocycle with 2-dimethylamino-5,7-dimethyloxazolo[4,5-b]pyridine-N-oxide 
undergoing regioselective functionalisation at the 7-methyl group on reaction with trifluoroacetic 
anhydride in contrast to the reaction of 4,6-dimethyl-3-hydroxypyridine-N-oxide with acetic 
anhydride that resulted in functionalisation of the 6-methyl group. To optimise selectivity for the 
A3 receptor, 5-aminomethyl-7-bromo-2-dimethylamino-4-[(3-methylisoxazol-5-
yl)methoxy]benzo[d]oxazole was synthesised and coupled with the 1-(6-chloropurin-9-yl)-1-deoxy-N-
methyl--D-ribofuranuronamide. The products were found to act as adenosine A3 agonists but further 
work is required to optimise potency and selectivity.        
 
 
 
 
 
 
 
 
Introduction 
 
The G-protein-coupled adenosine receptors are important in 
regulating a wide range of physiological functions. Specifically A3 
receptor agonists have been identified as being of interest for the 
treatment of cardiac ischaemia1 and many compounds have been 
evaluated for selective A3 receptor agonist activity.2 Indeed, N6 
substituted derivatives of adenosine and analogues have been found 
to exhibit useful A3 agonist activity, the N6-
(iodobenzyl)purinylribofuranuronamide 13a being an early example, 
see Figure 1, with many more homologues subsequently synthesized 
and evaluated.2,4 In particular, the N6-
(benzoxazolylmethyl)purinyluronamide 2 was identified as a 
promising lead.5 However, concerns about toxicity issues due to the 
iodine substituent and the possible improvement in selectivity 
following incorporation of an oxazolopyridine rather than a 
benzoxazole into the N6 substituent, led to the selection of the  
 
 
 
 
 
ribofuranuronamide 3 as the next target for synthesis,6 see Figure 2. 
We here report a synthesis of this compound and several of its 
homologues together with the results of preliminary biological 
evaluation of these compounds.  
 
 
 
Figure 1 Examples of adenosine A3 receptor agonists 
 
ARTICLE  
 
 
Figure 2 The N6-substituted purinylribofuranuronamide 3 selected 
for evaluation as an A3 receptor agonist 
 
 
Results and discussion    
 
Synthesis of oxazolopyridine derived adenosine derivatives 
 
Following well established literature precedent,2-4 the uronamide 3 
was to be prepared from the 2-dimethylamino-5-aminomethyl-7-
methyloxazolo[4,5-b]pyridine 5 and the known 6-
chloropurinyluronamide 4,7 the challenge in the work being to 
develop a synthesis of the oxazolopyridine 5. Initially it was 
intended to prepare this oxazolopyridine from 5,7-dimethyl-2-
dimethylamino-oxazolopyridine 6 by rearrangement of the 
corresponding pyridine N-oxide. In turn the oxazolopyridine 6 was 
to be prepared from 5-hydroxy-6-nitro-2,4-lutidine (7) that it was 
intended to prepare from 2,4-lutidine (8), see Figure 3.  
 
 
Figure 3 Planned synthesis of the target compound 3 
 
Nitration of 2,4-lutidine (8) using potassium nitrate in fuming 
sulfuric acid gave a mixture of 5-nitro-2,4-lutidine (9) and its 3-nitro 
isomer from which the required isomer 9 was isolated by fractional 
distillation albeit in only a low yield.8a Hydrogenation gave the 5-
amino-2,4-lutidine (10) that was converted into the 5-hydroxy-2,4-
lutidine (11) by diazotisation using sodium nitrite in aqueous sulfuric 
acid. In this reaction it was important to use just a small excess of 
sulfuric acid to avoid the formation of the pyrazolopyridine 12.9 
Nitration of the hydroxylutidine 11 using concentrated nitric and 
sulfuric acids10 led to decomposition but the use of ceric ammonium 
nitrate and sodium bicarbonate in acetonitrile heated under reflux11 
gave the required 5-hydroxy-6-nitro-2,4-lutidine (7) in a modest but 
reproducible yield. Hydrogenation of the nitrolutidine 7 gave the 
corresponding hydroxyaminolutidine 13 that was converted into the 
2-dimethylamino-oxazolopyridine 6 using dichloromethylene-
(dimethyl)ammonium chloride, see Scheme 1.  
  
 
 
Scheme 1 Synthesis and hydroxylation of the 2-dimethylamino-
oxazolopyridine 6 Reagents and conditions (i) fuming H2SO4, 0 oC, 
add KNO3, heat slowly to 100 oC, 8 h (17%); (ii) H2, Pd/C, MeOH, 
rt, 16 h (ca. 100%); (iii) aq. H2SO4, 0 oC, NaNO2, H2O, 0 oC, 15 
min, reflux 15 min (11, 47%; with a slight excess of H2SO4); (iv) 
CAN, NaHCO3, MeCN, reflux, 6 h (42%); (v) H2, Pd/C, EtOAc, rt, 
16 h; (vi) Cl2C=NMe2Cl, DCM, reflux, 5 h; (vii) mCPBA, CHCl3, rt, 
16 h (78%); (viii) (CF3CO)2O, DCM, reflux, 16 h (29%).  
 
Oxidation of the oxazolopyridine 6 using meta-chloroperoxybenzoic 
acid gave the N-oxide 14, an X-ray crystal structure confirming that 
the product was the pyridine N-oxide shown, see Figure 4. When this 
N-oxide was reacted with an excess of acetic anhydride, standard 
conditions for effecting regioselective hydroxylation of a methyl 
group ortho to an N-oxide,8,12 a mixture of several products was 
obtained. However, the use of trifluoroacetic anhydride in 
dichloromethane under reflux,13 followed by saponification, gave a 
single product 15 in which the methyl group remote from the N-
oxide had been hydroxylated, albeit in only a modest yield, see 
Scheme 1.   
 The regioselectivity of this hydroxylation was initially indicated 
by the 1H-15N gHMBC NMR spectrum that showed a three-bond 
coupling of 5.0 Hz between the remaining aryl methyl group at 1.5 
and the pyridine nitrogen in contrast to the small coupling of 0.5 Hz 
between the aryl methylene protons at  5.0 and the pyridine 
nitrogen. This structural assignment was eventually confirmed by X-
ray diffraction, see Figure 5.     
 
 
Figure 4 The structure of the N-oxide 14 as established by X-ray 
crystallography  
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Figure 5 The structure of 2-dimethylamino-7-hydroxymethyl-5-
methyloxazolo[4,5-b]pyridine (15) as established by X-ray 
crystallography  
 
The selective formation of the 7-hydroxymethyloxazolopyridine 15 
rather than its 5-hydroxymethyl isomer was unexpected since 
typically an ortho methyl group is hydroxylated on treatment of a 
pyridine N-oxide with an acyl anhydride.8 This meant that it was 
necessary to hydroxylate the ortho methyl group before assembling 
the oxazolopyridine.  
 In our hands, oxidation of the 5-hydroxy-2,4-lutidine 11 to its N-
oxide 16 was carried out using meta-chloroperoxybenzoic acid. The 
conversion of the N-oxide 16 into the bis-acetate 17 using acetic 
anhydride is known and proceded without incident, the structure of 
the product being assigned according to the literature.8 Selective 
deacetylation of the aromatic hydroxyl group was carried out using 
pyrrolidine in DCM,14 as sodium hydroxide was less selective and 
gave a mixture of products, and nitration of the resulting 
hydroxypyridine 18 to the nitropyridine 19 was best achieved using 
ceric ammonium nitrate as before. Attempts to reduce the 
nitropyridine 19 to the corresponding aminopyridine by 
hydrogenation were complicated by hydrogenolysis of the acetoxy 
group. To convert the acetoxy group into a less good leaving group, 
it was saponified to give the alcohol 20 and hydrogenation of this 
now proceeded uneventfully to give 2-amino-3-hydroxy-6-
hydroxymethyl-4-methylpyridine (21). However, it transpired that 
this compound was relatively insoluble in many organic solvents and 
correspondingly difficult to functionalise. The 
dihydroxynitropyridine 20 was therefore converted into its mono-
tert-butyldiphenylsilyl ether 22. Hydrogenation of this gave the 
aminopyridine 23 that on treatment with 
dichloromethylene(dimethyl)ammonium chloride gave the required 
oxazolopyridine 24. Desilylation provided the 5-hydroxymethyl-7-
methyloxazolo[4,5-b]pyridine 25, see Scheme 2.  
 The structures of the products in Scheme 2 were assigned on the 
basis of the literature precedent for the pyridine N-oxide reaction8 
and from spectroscopic data. The 5-hydroxymethyl-7-
methyloxazolopyridine 25 was distinctly different from its 7-
hydroxmethyl-5-methyl isomer 15 prepared earlier.     
 To complete the synthesis of the uronamide 3, the 
hydroxymethyloxazolopyridine 25 had to be converted into its 
aminomethyl homologue 5. This was achieved using a Mitsunobu 
reaction15 of the alcohol 25 with 2-nitrobenzene sulfonamide to 
prepare the N-alkylsulfonamide 26. This reaction was complicated 
by bis-alkylation of the 2-nitrobenzene sulfonamide but was not 
optimised at this stage. Desulfonylation gave the primary amine 5 
and coupling this with the 6-chloropurine 4 gave the N6-substituted 
purinyluronamide 27. Selective hydrolysis of this acetonide 27 gave 
the required ribofuranuronamide 3, see Scheme 3.  
 The products in Scheme 3 were identified on the basis of their 
spectrocopic data. Following evaluation of the uronamide 3 for 
biological activity, vide infra, it was decided to prepare homologues 
for further studies.  
 
Scheme 2 Preparation of the 5-hydroxymethyloxazolopyridine 25 
Reagents and conditions (i) mCPBA, DCM, rt, 16 h (85%); (ii) 
Ac2O, 110 oC, 2.5 h (80%); (iii) pyrrolidine, DCM, rt, 16 h (ca. 
100%); (iv) CAN, NaHCO3, MeCN, reflux, 5 h (38%); (v) NaOH, 
MeOH, rt, 1 h; (vi) H2, Pd/C, EtOAc, rt, 2 h; (vii) tBuPh2SiCl, imid., 
DMF, rt, 12 h (75%); (viii) H2, Pd/C, EtOAc, rt, 16 h; (ix) 
Cl2C=NMe2Cl, Et3N, DCM, reflux, 6 h (86%); (x) TBAF, THF, rt, 1 
h (92%).  
 
 
 
Scheme 3 Completion of a synthesis of the A3 receptor agonist 3 
Reagents and conditions (i) 2-O2NC6H4SO2NH2, Ph3P, THF, 
iPrO2CN=NCO2iPr, rt, 16 h (31%); (ii) PhSH, K2CO3, MeCN, rt, 16 
h (84%); (iii) 4, Et3N, EtOH, 80 oC, 16 h (90%); (iv) aq. HCl, 65 oC, 
1 h (76%).  
 
 The next compound identified for synthesis was the 
diethylamino analogue 37, see Scheme 4. This required the synthesis 
of the 2-diethylamino-5-aminomethyl-7-methyloxazolo[4,5-
b]pyridine 35. As dichloromethylene(diethyl)ammonium chloride 
was not commercially available at the time, the original synthesis 
had to be modified. Therefore, following the literature precedent, the 
aminophenol 23 was converted into the thione 28 using carbon 
disulfide and potassium hydroxide in ethanol,16 the product being 
identified as the thione tautomer by analogy with the literature.17 The 
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attempted direct conversion of the thione 28 into the corresponding 
diethylamino-oxazole using diethylamine delivered unchanged 
starting material, perhaps because of the volatility of diethylamine. 
The thione was therefore converted into the 2-chloro-oxazole 29 
using thionyl chloride. Displacement of chloride using diethylamine 
gave the required 2-diethylamino-oxazole 3017 that was desilylated 
to give the alcohol 31. To avoid the bis-alkylation side-reaction 
observed during the synthesis of the amine 5, the Mitsunobu reaction 
of the alcohol 31 was carried out using the N-Boc-protected 2-
nitrobenzene sulfonamide 32.18 A good yield of the alkylated 
sulfonamide 33 was obtained and, following removal of the Boc-
group, denosylation of the resulting sulfonamide 3419 gave the 
required primary amine 35, see Scheme 4.   
  The primary amine 35 was coupled with the 6-chloropurine 4 as 
before to obtain the N6-substituted purinyluronamide 36 and this 
was deprotected to give the target uronamide 37, see Scheme 4. The 
structures of the products in Scheme 4 were assigned using 
spectroscopic data. 
 
 
 
 
Scheme 4 Synthesis of the diethylamino substituted adenosine 
uronamide 37 Reagents and conditions (i) CS2, KOH, EtOH, reflux, 
3 h (83%); (ii) SOCl2, Na2CO3, benzene, 50 oC, 3 h; (iii) Et2NH, 
benzene, rt, 1 h (70% from 28); (iv) TBAF, THF, rt, 1 h (93%); (v) 
Ph3P, THF, DIAD, rt, 16 h (98%); (vi) TFA, rt, 1 h (79%); (vii) 
PhSH, K2CO3, MeCN, rt, 16 h (85%); (viii) 4, Et3N, EtOH, reflux, 
16 h (55%); (ix) aq. HCl, 65 oC, 1 h (46%).    
 
 At this point it was decided to investigate the effect of a methyl 
substituent on the methylene group attached to N6. This introduces a 
new stereogenic centre but initially mixtures of epimers were 
prepared for studies of their biological activity although the 
synthesis that was developed could be modified to control the 
chirality at this position if required, see Scheme 5.  
 Oxidation of the alcohols 25 and 31 gave the corresponding 
aldehydes 38 and 39. Reaction of these with racemic tert-
butanesulfinamide gave the racemic sulfinimides 40 and 41.20 The 
reaction of these with methylmagnesium bromide was 
stereoselective and gave, in each case, essentially a single, albeit 
racemic, adduct 42 and 43. The relative configurations of the two 
stereogenic centres were assigned by analogy with the literature.21 
Methanolysis gave the racemic amines 44 and 45 and these were 
coupled with the 6-chloropurine 4 to give mixtures of the epimeric 
purinyluronamides 46 and 47. A small amount of kinetic resolution 
was observed in these reactions as the products were found to 
correspond to 60 : 40 mixtures of the two diastereoisomers. Finally 
deprotection gave the target compounds 48 and 49. Again mixtures 
of epimers were obtained but as the Grignard addition reactions had 
been highly diastereoselective, the use of enantiomerically enriched 
tert-butanesulfinamide would have delivered one or other of the 
epimers selectively. The structures shown were assigned to the 
products in Scheme 5 using spectroscopic data.   
  
 
Scheme 5 Synthesis of adenosine uronamides 48 and 49 Reagents 
and conditions (i) Dess-Martin periodinane, DCM, rt, 20 min; (ii) 
(±)-tBuS(O)NH2, CuSO4, DCM, rt, 16 h ( (40, 70% from 25; 41, 
90% from 31); (iii) MeMgBr, THF, 78 oC, 1 h (42, 76%; 43, 76%); 
(iv) aq. HCl, dioxane, MeOH, rt, 30 min (44, 83%; 45, 82%); (v) 4, 
Et3N, EtOH, reflux, 16 h; (vi) aq. HCl, 65 oC, 1 h (48, 50% from 44; 
49, 60% from 45).   
 
Synthesis of an N6-benzoxazolylmethylpurinyluronamide  
 
Although the biological activities of the uronamides 3, 36, 48 and 49 
were promising, it was decided that further structural changes in the 
N6 substituent were required to achieve the required biological 
activity and selectivity. The (N6-benzoxazolylmethylpurinyl)-
uronamide 50 was selected as the next synthetic target, see Figure 4.6 
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This is analogous to the known agonist 2 but with a bromine 
substituent rather than the labile iodide and an extra hetarylmethoxy 
substituent to facilitate selective binding.  
 
 
 
Figure 4 The strategy for the synthesis of the (N6-
benzoxazolylpurinyl)uronamide 50 
 
As before it was the synthesis of the heavily substituted benzoxazole 
51 that constituted the challenge in preparing uronamide 50. 
Embedded within the benzoxazole is a pentasubstituted benzene 
ring. It was decided to use 2-nitroresorcinol (52) as the starting 
material for this synthesis, see Figure 4. The conversion of this 
resorcinol into the benzoxazole 51 would require introduction of the 
bromine and aminomethyl substituents and discrimination between 
the two hydroxyls so that one could be incorporated into the oxazole 
and the other one alkylated.  
 Initial studies involved the known22 carboxymethylation of the 
protected aminoresorcinol 53 that was readily available from 2-
nitroresorcinol in three steps. However in our hands only complex 
mixtures of products were obtained using n-butyllithium and either 
Mander’s reagent23 or methyl chloroformate as the electrophile, see 
Scheme 6.    
 
Scheme 6 Unsuccessful carboxymethylation of the protected 
resorcinol 53. 
 
Carboxymethylation of the bis-MOM-protected iodonitroresorcinol 
56 using phenylmagnesium bromide to effect halogen-metal 
exchange followed by reaction of the organometallic intermediate 
with Mander’s reagent is reported to give the regioselectively 
monodeprotected ester 57, see Scheme 7.24 The starting material 56 
for this conversion is available in two steps from 2-nitroresorcinol 
52.24 However, in our hands the reported procedure for the 
conversion of the iodide 56 into the ester 57 gave a complex mixture 
of products. Attempts to effect this conversion using different 
electrophiles were similarly unsuccessful. However, studies into 
palladium(0) catalysed methoxycarbonylation procedures were more 
successful.25,26 The optimum catalyst system was palladium(II) 
acetate and the hindered electron-rich 2,3,5,7-tetramethyl-2,4,8-
trioxa-6-phenyl-6-phospha-adamantane 65 with methanol as the 
solvent rather than a methanol – N,N-dimethylformamide mixed 
solvent system, and gave an excellent yield of the mono-deprotected 
ester 57 after 12 h at 80 oC, see Scheme 7.  
 The regioselectivity of the monodeprotection was not confirmed 
at this stage but the product had NMR data identical to those 
reported in the literature for isomer 57.24  
 Bromination of ester 57 was regioselective as would be expected 
but was accompanied by loss of the remaining MOM-ether and gave 
the resorcinol 58. This was slighly disappointing since it meant that 
discrimination between the two hydroxyl groups had to be carried 
out. Nevertheless the synthesis was continued in that reduction of the 
nitro group was achieved using zinc and acetic acid in methanol, 
conditions known to be compatible with both phenolic and ester 
groups, to give the aminoresorcinol 59. 
 At this point it was decided to investigate the introduction of the 
oxazole since it was hoped that hydrogen bonding between the ester 
and the ortho phenolic hydroxyl group would reduce its reactivity 
relative to the hydroxyl group that was para to the carboxymethyl 
substituent. In the event, reaction with dichloromethylene-
(dimethyl)ammonium chloride gave a single product that was 
provisionally identified as the required isomer 60. This structural 
assignment was confirmed later in the synthesis.  
 With the assumption that the oxazole was the required 
regioisomer 60, the free hydroxyl group was alkylated using 5-
hydroxymethyl-3-methylisoxazole under Mitsunobu conditions to 
provide 61. Reduction of the ester 61 using lithium aluminium 
hydride was accompanied by debromination but calcium 
borohydride27 was both sufficiently reactive and selective and gave 
the alcohol 62 in a good yield. Long-range correlation in the 1H 
NMR spectrum of the alcohol 62 between the two benzylic 
methylene groups were consistent with the required ortho-orientation 
of the hydroxymethyl and alkoxy side chains and the structure of the 
alcohol 62 was finally confirmed by X-ray diffraction, see Figure 5. 
 
 
 
 
Figure 5 The structure of the alcohol 62 as confirmed by X-ray 
diffraction 
 
The alcohol 62 was converted into the required primary amine 51 by 
a Mitsunobu reaction using 2-nitrobenzene sulfonamide, 
monoalkylation being the major reaction pathway in this hindered 
system. Denosylation of the intermediate sulfonamide 63 then gave 
the primary amine 51. Substitution of the chloride from the 6-
chloropurine 4 using the amine 51 proceded uneventfully, and 
deprotection of the resulting acetonide 64 gave the required N6-
substituted purinyluronamide 50.  
 This potentially selective adenosine A3 receptor agonist 50 had 
been prepared in twelve steps from the commercially available 
resorcinol 62 in an overall yield of 21%. The structures of the 
products shown in Scheme 7 were consistent with their 
spectroscopic data, the structures of the benzoxazoles being 
confirmed by the X-ray crystal structure of the alcohol 62.   
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Summary and conclusions 
 
Compounds 3, 36, 48, 49 and 50, were screened for activity as 
adenosine A3 receptor agonists and were found to demonstrate 
useful activity.  
 Of interest in the synthetic work described here is the 
unexpected regioselectivity of the redox reaction of the pyridine N-
oxide 14 since usually an ortho-methyl substituent is oxidised in 2,4-
dimethylpyridines,12 as was observed for the analogous reaction of 
the 5-hydroxy-2,4-dimethylpyridine N-oxide 16. The origin of this 
unexpected regioselectivity in the reaction of pyridine N-oxide 14 is 
not obvious, but must involve the selective deprotonation of the 7-
methyl group to give the p-quinoidal intermediate 66 that reacts with 
trifluoroacetate via an intermolecular process, see Figure 6. 
Hydrolysis of the resulting product 67 could then deliver the 
observed product 15. The oxazole ring clearly has a role in 
influencing this regioselectivity and may well be protonated or 
trifluoroacetylated under the reaction conditions. The enhanced 
acidity of the p-methyl group may then be due to an electrostatic 
effect involving the proximate oxazole ring.  
 
Figure 6 Intermediates that may be involved with the regioselective 
redox reaction of pyridine N-oxide 14 
Other aspects of the syntheses that may be of some interest are the 
mild conditions used for the nitration of the hydroxypyridines 11 and 
18; the improved conditions of the conversion of iodide 56 into the 
ester 57, and the acccompanying regioselective monodeprotection; 
the regioselective formation of the benzoxazole 60; and the overall 
strategies used in the synthesis of the highly substituted pyridine and 
benzene derivatives used in this work. Further studies leading to the 
additional development of these adenosine A3 receptor agonists 
would be of interest. 
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Experimental   
 
General experimental details 
 
1H and 13C NMR spectra were recorded on Varian Unity Inova 400 
and Varian Unity Inova 300 spectrometers with residual non-
deuterated solvent as the internal standard. Only distinguishable 
peaks are reported for minor isomers in isomeric mixtures. IR 
spectra were recorded on an ATI Mattson Genesis FTIR as thin films 
produced by evaporation of a dichloromethane solution on sodium 
chloride plates unless otherwise stated. Mass spectra were recorded 
on Fison VG Trio 2000 and Kratos Concept spectrometers. 
Chromatography refers to flash column chromatography using 
Merck silica gel 60 H (230-300 mesh). Tetrahydrofuran (THF) was 
dried and distilled from sodium metal using benzophenone as an 
indicator under an atmosphere of nitrogen. Dichloromethane was 
dried and distilled from calcium hydride under an atmosphere of 
nitrogen. Ether refers to diethyl ether, which was dried and distilled 
from sodium metal using benzophenone as an indicator under an 
atmosphere of nitrogen. Light petroleum refers to the fraction of 
petroleum ether distilled between 40-60 C. Benzene and hexane 
were dried over sodium metal. Butyllithium (1.6 M in hexanes) was 
titrated against a solution of propan-2-ol in xylene with 2,2-
bipyridine as an indicator. Triethylamine and di-isopropylamine 
were dried over potassium hydroxide pellets. Brine refers to 
saturated aqueous sodium chloride.  
 
4,6-Dimethyl-3-hydroxy-2-nitropyridine (7) 
Fuming sulfuric acid (147 g, 1.498 mol) was added slowly with 
stirring to 2,4-lutidine (8) (15 g, 140 mmol) cooled in an ice bath. 
Potassium nitrate (25.5 g, 252 mmol, 1.8 eq) was added slowly, and 
the reaction mixture gradually heated to 100 °C and maintained at 
this temperature for 8 h. The reaction mixture was then heated at 120 
°C for 8 h. After cooling to rt, the reaction mixture was poured onto 
ice (300 g), then neutralized to pH 7 using K2CO3 and filtered. The 
filtrate was extracted with chloroform (5  300 mL) and the organic 
extracts were dried (Na2SO4) then concentrated under reduced 
pressure and the residue distilled to give 5-nitro-2,4-lutidine (9)8a as 
a pale oil (3.62 g, 17%), b.p. 79 °C (3.73 mm Hg) [lit.8a 44 °C (0.17 
mm Hg)], Rf 0.60 (Et2O); Ȟmax/cm-1 2930, 1610, 1557, 1519, 1346 
and 838; δH (300 MHz, CDCl3) 2.62 and 2.63 (each 3 H, s, CH3), 
7.15 (1 H, s, 3-H) and 9.10 (1 H, s, 6-H); δC (75 MHz, CDCl3) 20.5, 
24.5, 126.9, 143.6, 145.9 and 163.5; m/z (ES+) 153.1 (M+ + 1, 
100%). 
       Palladium on charcoal (10%, 280 mg, 2 mol%) was added to 5-
nitro-2,4-lutidine (9) (2 g, 13.1 mmol) in methanol (39 mL). The 
mixture was stirred at rt under hydrogen at atmospheric pressure for 
16 h then filtered, and concentrated under reduced pressure to leave 
5-amino-2,4-lutidine (10)8a (1.67 g, ca. 100%) used without 
purification, Rf 0.13 (10% MeOH/Et2O); Ȟmax/cm-1 3375, 3338, 3209, 
1651, 1612, 1505, 1448, 1242 and 868; δH (300 MHz, CDCl3) 2.12 
(3 H, s, 4-CH3), 2.39 (3 H, s, 2-CH3), 3.37 (2 H, br. s, 3-NH2), 6.82 
(1 H, s, 3-H) and 7.91 (1 H, s, 6-H); δC (75 MHz, CDCl3) 17.0, 23.4, 
124.8, 131.8, 136.3, 139.1 and 148.6; m/z (ES+) 123.1 (M+ + 1, 
100%). 
       Sodium nitrite (1.47 g, 21.3 mmol, 1.1 eq) in water (15 mL) was 
added over a period of 7 min to 5-amino-2,4-lutidine (10) (2.37 g, 
19.4 mmol) in aqueous sulfuric acid (4.8%, 37.8 mL) cooled to 0 °C 
using dry ice/acetone bath. The solution was maintained at 0 °C for 
15 min and then heated under reflux for 5 min. After cooling to room 
temperature, the solution was neutralised to pH 7 with K2CO3 and 
the mixture extracted with methanol in dichloromethane (10%, 10  
100 mL). The organic extracts were dried (Na2SO4) and concentrated 
under reduced pressure. Chromatography of the residue (50% to 
90% Et2O/light petroleum) gave 5-hydroxy-2,4-lutidine (11)8a as a 
white solid (1.13 g, 47%), m.p. 146-148 °C (lit.8a 146-148 °C), Rf 
0.61 (10% MeOH/Et2O)ν Ȟmax/cm-1 2922, 2618, 2554, 1612, 1504, 
1462, 1423, 1295, 1219 and 946ν δH (300 MHz, CDCl3) 2.28 (3 H, s, 
4-CH3), 2.46 (3 H, s, 2-CH3), 6.98 (1 H, s, 3-H) and 8.08 (1 H, s, 6-
H)ν δC (75 MHz, CDCl3) 16.1, 22.1, 126.5, 134.0, 137.2, 147.8 and 
152.4; m/z (ES+) 124.2 (M++ 1, 100%). 
       Ceric ammonium nitrate (8.90 g, 16.24 mmol, 2.0 eq) was added 
to 5-hydroxy-2,4-lutidine (11) (1.00 g, 8.12 mmol) and NaHCO3 
(2.05 g, 24.36 mmol, 3.0 eq) in anhydrous acetonitrile (93 mL) at rt. 
The mixture was heated under reflux for 6 h then filtered and the 
filtrate concentrated under reduced pressure. The residue was taken 
up into water (30 mL) and extracted with dichloromethane (3  30 
mL). The organic extracts were dried (Na2SO4), and concentrated 
under reduced pressure. Chromatography of the residue (10% to 
30% Et2O/light petroleum) gave the title compound 7 as yellow solid 
(577 mg, 42%), Rf 0.63 (Et2O), m.p. 63-65 °Cν Ȟmax/cm-1 3228, 2966, 
2933, 1573, 1538, 1479, 1447, 1385, 1360, 1323, 1256, 1229, 1184, 
1036, 1019, 913, 896, 807, 772 and 765ν δH (300 MHz, CDCl3) 2.42 
(3 H, s, CH3), 2.57 (3 H, s, CH3), 7.36 (1 H, s, 5-H) and 10.45 (1 H, 
s, 3-OH)ν δC (100 MHz, CDCl3) 15.8, 23.3, 133.0, 141.1, 141.4, 
148.3 and 149.0; m/z (ES) 151.2 (M+  1, 100%). 
 
5,7-Dimethyl-2-dimethylamino-oxazolo[4,5-b]pyridine (6) 
A mixture of the nitropyridine 7 (768 mg, 4.60 mmol) and palladium 
on charcoal (10%, 10 mg, 2 mol%) in ethyl acetate (17 mL) was 
stirred at rt for 16 h under an atmosphere of hydrogen then filtered 
through a pad of Celite.® The filtrate was concentrated under 
reduced pressure to leave 2-amino-3-hydroxy-4,6-dimethylpyridine 
13 (660 mg) used without purification, Rf 0.15 (10% MeOH/Et2O); 
δH (300 MHz, CDCl3) 2.18 and 2.27 (each 3 H, s, CH3), 6.30 (1 H, s, 
5-H) and 6.55 (3 H, br. s, NH2 and OH)ν δC (75 MHz, CDCl3) 16.4, 
21.2, 116.3, 134.7, 139.4, 139.9 and 149.8; m/z (ES+) 139 (M+ + 1, 
100%). 
         A solution of 2-amino-3-hydroxy-4,6-dimethylpyridine 13 
(685 mg, 4.96 mmol) and dichloromethylene(dimethyl)ammonium 
chloride (1.29 g, 7.93 mmol, 1.6 eq) in dry dichloromethane (52 mL) 
was heated under reflux for 5 h. After cooling, the mixture was 
poured into saturated aqueous sodium bicarbonate (30 mL) and the 
mixture extracted with dichloromethane (4  30 mL). The organic 
extracts were washed with brine, dried (MgSO4) and concentrated 
under reduced pressure to give the title compound 6 as a pale solid 
(1.05 g) used without purification, Rf 0.38 (10% MeOH/Et2O), m.p. 
128-130 °C (Found: M+ + H, 192.1134. C10H14N3O requires M, 
192.1131)ν Ȟmax/cm-1 2952, 2925, 1664, 1644, 1567, 1446, 1425, 
1379, 1223, 1192, 1142, 1044, 956, 892, 875 and 730. δH (300 MHz, 
CDCl3) 2.39 and 2.53 (each 3 H, s, CH3), 3.26 [6 H, s, 2-N(CH3)2] 
and 6.60 (1 H, s, 6-H)ν δC (125 MHz, CDCl3) 13.6, 22.9, 36.4, 115.6, 
125.3, 138.2, 151.9, 156.5 and 163.2; m/z (ES+) 405.2 (2M+ + 23, 
18%), 383.2 (2M+ + 1, 11) and 192.2 (M+ + 1, 100). 
 
5,7-Dimethyl-2-dimethylamino-oxazolo[4,5-b]pyridine 4-oxide 
(14) 
m-Chloroperoxybenzoic acid (77%, 1.60 g, 7.14 mmol, 1.3 eq) was 
added to the oxazolopyridine 6 (1.05 g, 5.49 mmol) in chloroform 
(11 mL) and the mixture stirred for 16 h. After concentrated under 
reduced pressure, chromatography of the residue (5% to 10% 
MeOH/CH2Cl2) gave the title compound 14 (1.09 g, 78%), Rf 0.13 
(30% MeOH/Et2O), m.p. 204-206 °C (Found: M+ + H, 208.1084. 
C10H14N3O2 requires M, 208.1081)ν Ȟmax/cm-1 3396, 2927, 1675, 
1592, 1464, 1426, 1375, 1358, 1234, 1190, 1118, 943, 891, 748 and 
723ν δH (300 MHz, CDCl3) 2.37 and 2.57 (each 3 H, s, CH3), 3.29 [6 
H, s, 2-N(CH3)2] and 6.65 (1 H, s, 6-H); m/z (ES+) 437.3 (2M+ + 23, 
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70%), 414.9 (2M+ + 1, 25), 230.1 (M++ 23, 62) and 208.2 (M++ 1, 
100). 
 
2-Dimethylamino-7-hydroxymethyl-5-methyloxazolo[4,5-
b]pyridine (15) 
Trifluoroacetic anhydride (5.20 mL, 37.21 mmo1, 10.0 eq.) was 
added to the N-oxide 14 (771 mg, 3.72 mmol) in dry 
dichloromethane (21 mL) and the mixture heated under reflux for l6 
h. After concentration under reduced pressure, the solid residue was 
dissolved in dichloromethane (15 mL). Aqueous potassium 
carbonate (2 M, 5 mL) was added and the biphasic mixture stirred 
for 1 h. Water (10 mL) was added and the aqueous phase was 
extracted with dichloromethane (6  15 mL). The organic extracts 
were washed with brine, dried (MgSO4) and concentrated under 
reduced pressure. Chromatography of the residue (Et2O% to 10% 
MeOH/Et2O) gave the title compound 15 as a pale solid (220 mg, 
29%), Rf 0.17 (10% MeOH/Et2O), m.p. 188-190 °C (Found: M+ + H, 
208.1088, C10H14N3O2 requires M, 208.1081)ν Ȟmax/cm-1 3163, 2925, 
1664, 1640, 1567, 1399, 1283, 1195, 1043, 891 and 725ν δH (300 
MHz, CDCl3) 2.54 (3 H, s, 5-CH3), 3.24 [6 H, s, 2-N(CH3)2], 4.88 (2 
H, s, 7-CH2) and 6.84 (1 H, s, 6-H)ν δC (125 MHz, CDCl3) 22.9, 
36.5, 57.5, 112.1, 129.3, 136.0, 152.0, 156.6 and 163.3; m/z (ES+) 
437.1 (2M+ + 23, 21%) and 208.2 (M+ + 1, 100). 
 
2-Acetoxymethyl-5-hydroxy-4-methylpyridine (18) 
m-Chloroperoxybenzoic acid (77%, 2.25 g, 10.5 mmol, 1.1 eq) was 
added to 2,4-dimethyl-5-hydroxypyridine 8 (1.13 g, 9.17 mmol) in 
dichloromethane (18 mL) and the mixture stirred at rt for 16 h. After 
concentration under reduced pressure, chromatography of the residue 
(Et2O to 10% MeOH/Et2O) gave 2,4-dimethyl-5-hydroxypyridine N-
oxide (16)8a (1.09 g, 85%), m.p 227-229 °C (lit.8a 229 °C), Rf 0.55 
(10% MeOH/Et2O)ν Ȟmax/cm-1 3390, 2961, 2921, 1514, 1491, 1434, 
1310, 1189, 1105, 879 and 844ν δH (300 MHz, CD3OD) 2.25 (3 H, s, 
4-CH3), 2.43 (3 H, s, 2-CH3), 7.26 (1 H, s, 3-H) and 7.89 (1 H, s, 6-
H)ν δC (75 MHz, CD3OD) 13.9, 15.4, 126.1, 127.7, 131.1, 140.2 and 
153.0; m/z (ES+) 140.1 (M+ + 1, 100%). 
       A mixture of 2,4-dimethyl-5-hydroxypyridine N-oxide (16) 
(1.09 g, 7.8 mmol) and acetic anhydride (20 mL) was heated at 110 
°C with stirring for 2.5 h. After cooling and concentration under 
reduced pressure, chromatography of the residue (30% to 50% 
Et2O/light petroleum) gave 5-acetoxy-2-acetoxymethyl-4-
methylpyridine (17)8a as a pale oil (1.40g, 80%), Rf 0.11 (50% 
Et2O/light petroleum)ν Ȟmax/cm-1 1760, 1747, 1609, 1486, 1440, 
1371, 1268, 1232, 1218, 1194, 1135, 1048, 1013 and 892ν δH (300 
MHz, CDCl3) 2.16 [3 H, s, 2-CH2OC(O)CH3], 2.23 [3 H, s, 5-
OC(O)CH3], 2.36 (3 H, s, 4-CH3), 5.18 (2 H, s, 2-CH2), 7.16 (1 H, s, 
3-H) and 8.28 (1 H, s, 6-H)ν δC (75 MHz, CDCl3) 16.2, 20.9, 21.2, 
66.6, 124.6, 140.5, 143.5, 146.2, 153.2, 169.0 and 170.9; m/z (CI+) 
224 (M+ + 1, 100%). 
        Pyrrolidine (215 µL, 2.57 mmol) was added to the bis-acetate 
17 (574 mg, 2.57 mmol) in dichloromethane (7.2 mL) and the 
mixture stirred at rt for 16 h. After concentration under reduced 
pressure, chromatography of the residue (50% to 100% Et2O/light 
petroleum) gave the title compound 18 as a pale oil (467 mg, ca. 
100%), Rf 0.23 (Et2O) (Found : M+ + Na, 204.0627. C9H11NO3Na 
requires M, 204.0631); Ȟmax/cm-1 3028, 2959, 1747, 1611, 1505, 
1455, 1363, 1293, 1229, 1032 and 879; δH (300 MHz, CDCl3) 2.10 
(3 H, s, CH3CO), 2.34 (3 H, s, 4-CH3), 5.16 (2 H, s, 2-CH2), 7.25 (1 
H, s, 3-H) and 8.16 (1 H, s, 6-H); δC (75 MHz, CDCl3) 16.2, 21.1, 
65.9, 126.4, 134.7, 137.2, 145.4, 154.0 and 171.1; m/z (ES+) 204 
(M+ + 23, 25%) and 182 (M+ + 1, 100). 
 
2-Acetoxymethyl-5-hydroxy-4-methyl-6-nitropyridine (19) 
Ceric ammonium nitrate (1.55 g, 2.84 mmol, 1.1 eq) was added to 2-
acetoxymethyl-5-hydroxy-4-methylpyridine (18) (467 mg, 2.58 
mmol), and sodium hydrogen carbonate (346 mg, 4.12 mmol, 1.6 eq) 
in anhydrous acetonitrile (29 mL) at rt and the mixture stirred under 
reflux for 5 h. The mixture was filtered, and the filtrate washed with 
water then extracted with dichloromethane (3  20 mL). The organic 
extracts were dried (Na2SO4), and concentrated under reduced 
presure. Chromatography of the residue (10% to 30% Et2O/light 
petroleum) gave the title compound 19 as yellow solid (223 mg, 
38%), Rf 0.65 (Et2O), m.p. 84-87 °C (Found: M+ + Na, 249.0489. 
C9H10N2O5Na requires M, 249.0482)ν Ȟmax/cm-1 3297, 2962, 1744, 
1615, 1573, 1543, 1482, 1440, 1410, 1380, 1356, 1322, 1229, 1049, 
917 and 773ν δH (300 MHz, CDCl3) 2.16 (3 H, s, CH3CO), 2.44 (3 
H, s, 4-CH3), 5.16 (2 H, s, 2-CH2), 7.55 (1 H, s, 3-H) and 10.19 (1 H, 
br. s, 5-OH)ν δC (75 MHz, CDCl3) 16.2, 21.1, 65.9, 131.6, 141.2, 
142.6, 146.3, 149.6 and 170.8; m/z (ES) 225 (M+  1, 100%).  
 
3-Hydroxy-6-hydroxymethyl-4-methyl-2-nitropyridine (20) 
Aqueous sodium hydroxide (2 M, 2.21 mL, 4.42 mmol, 2.0 eq) was 
added to the acetoxymethylpyridine 19 (500 g, 2.21 mmol) in 
methanol (16 mL) and the mixture was stirred at rt for 1 h. After 
concentration under reduced pressure, the residue was taken up in 
water (15 mL) and the solution neutralised using aqueous hydrogen 
chloride (2 M) and extracted with dichloromethane (6  20 mL). The 
organic extracts were dried (Na2SO4) and concentrated under 
reduced pressure to give the title compound 20 that was used without 
purification, Rf 0.52 (Et2O), m.p. 136-139 °C (Found: M+ + Na, 
207.0380. C7H8N2O4Na requires M, 207.0376)ν Ȟmax/cm-1 3321, 
2474, 1535, 1478, 1362, 1307, 1257, 1200 and 1089ν δH (300 MHz, 
CD3OD) 2.45 (1 H, s, 4-CH3), 4.63 (2 H, s, 6-CH2) and 7.74 (1 H, s, 
5-H)ν δC (75 MHz, CD3OD) 15.0, 63.6, 129.7, 142.5, 147.8 and 
151.3; m/z (ES+) 207.1 (M+ + 23, 100%) and 185.1 (M+ + 1, 32). 
 
2-Amino-3-hydroxy-6-hydroxymethyl-4-methylpyridine (21) 
A mixture of the nitropyridine 20 (52 mg, 0.19 mmol) and palladium 
on charcoal (10%, 10 mg) in ethyl acetate (15 mL) was stirred at rt 
for 2 h under an atmosphere of hydrogen. The reaction mixture was 
then filtered through a pad of Celite® and the filtrate concentrated 
under reduced pressure to leave the title compound 21, Rf  0.07 (20% 
MeOH/Et2O) (Found: M+ + H, 155.0820. C7H11N2O2 requires M, 
155.0815); δH (300 MHz, CD3OD) 2.22 (3 H, s, 4-CH3), 4.44 (2 H, 
s, 6-CH2) and 6.57 (1 H, s, 5-H); m/z (CI+) 155 (M+ + 1, 100%) and 
154 (93). 
 
6-tert-Butyldiphenylsilyloxymethyl-3-hydroxy-4-methyl-2-
nitropyridine (22) 
tert-Butyldiphenylsilyl chloride (245 µL, 0.94 mmol, 1.05 eq) was 
added to the hydroxymethylpyridine 20 (165 mg, 0.90 mmol) and 
imidazole (305 mg, 4.48 mmol, 5 eq) in N,N-dimethylformamide 
(3.6 mL) and the mixture was stirred at room temperature for 12 h. 
Water (20 mL) was added and the mixture was extracted with 
dichloromethane (6  20 mL). The organic extracts were dried 
(Na2SO4) and concentrated under reduced pressure. Chromatography 
of the residue (2% to 10% Et2O/light petroleum) gave the title 
compound 22 as a yellow solid (285 mg, 75%), Rf 0.63 (Et2O), m.p. 
84-86 °C (Found: M+ + H, 423.1746. C23H27N2O4Si requires M, 
423.1735); Ȟmax/cm-1 3233, 2957, 2929, 2857, 1577, 1540, 1473, 
1427, 1409, 1358, 1307, 1263, 1111, 824, 741 and 701; δH (300 
MHz, CDCl3) 1.18 [9 H, s, SiC(CH3)3], 2.49 (3 H, s, 4-CH3), 4.85 (2 
H, s, 6-CH2), 7.39-7.51 (6 H, m, ArH), 7.68-7.72 (4 H, m, ArH), 
7.83 (1 H, s, 5-H), 10.47 (1 H, s, OH); δC (75 MHz, CDCl3) 16.5, 
19.6, 27.2, 66.1, 128.1, 130.0, 130.2, 133.0, 135.8, 142.1, 149.0 and 
151.5; m/z (ES+) 867.6 (2M+ + 23, 57%), 445.3 (M+ + 23, 75%) and 
423.3 (M+ + 1, 100).  
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2-Amino-6-tert-butyldiphenylsilyloxymethyl-3-hydroxy-4-
methylpyridine (23)  
A mixture of the nitropyridine 22 (285 mg, 0.67 mmol) and 
palladium on charcoal (10%, 14 mg, 2 mol%) in ethyl acetate (2.5 
mL) was stirred at rt for 16 h under an atmosphere of hydrogen. The 
reaction mixture was then filtered through a pad of Celite® and the 
filtrate was concentrated under reduced pressure to give the title 
compound 23 (290 mg) used without further purification, Rf 0.21 
(Et2O), m.p. 131–133 °C (Found: M+ + H, 393.1999. C23H29N2O2Si 
requires M, 393.1993)ν Ȟmax/cm-1 3478, 3377, 2957, 2930, 2857, 
1623, 1474, 1427, 1162, 1113, 823, 740 and 702ν δH (300 MHz, 
CDCl3) 1.13 [9 H, s, SiC(CH3)3], 2.18 (3 H, s, 4-CH3), 4.64 (2 H, s, 
6-CH2), 5.02 (3 H, br. s, 2-NH2 and 3-OH), 6.71 (1 H, s, 5-H), 7.35-
7.47 (6 H, m, ArH) and 7.69-7.72 (4 H, m, ArH)ν δC (75 MHz, 
CDCl3) 16.1, 19.6, 27.2, 65.7, 113.4, 128.0, 130.0, 133.1, 133.6, 
135.1, 135.8, 137.2 and 149.1; m/z (ES+) 393.3 (M+ + 1, 100%). 
 
5-tert-Butyldiphenylsilyloxymethyl-2-dimethylamino-7-
methyloxazolo[4,5-b]pyridine (24) 
A solution of the pyridine 23 (265 mg, 0.67 mmol), 
dichloromethylene(dimethyl)ammonium chloride (175 mg, 1.08 
mmol, 1.6 eq), and triethylamine (301 µL, 2.16 mmol, 3.2 eq) in dry 
dichloromethane (7.1 mL) was heated under reflux for 6 h. After 
cooling, the solution was poured into saturated aqueous sodium 
bicarbonate (20 mL) and the mixture extracted with dichloromethane 
(4  20 mL). The organic extracts were washed with brine, dried 
(MgSO4) and concentrated under reduced pressure. Chromatography 
of the residue (10% MeOH/CH2Cl2) gave the title compound 24 as a 
pale oil (260 mg, 86%), Rf 0.16 (Et2O) (Found: M+ + H, 446.2257. 
C26H32N3O2Si requires M, 446.2258); Ȟmax/cm-1 2952, 2931, 2857, 
2359, 2346, 1660, 1570, 1428, 1386, 1139, 1112, 1089, 894 and 
837; δH (300 MHz, CDCl3) 1.17 [9 H, s, SiC(CH3)3], 2.48 (3 H, s, 7-
CH3), 3.25 [6 H, s, 2-N(CH3)2], 4.90 (2 H, s, 5-CH2), 7.13 (1 H, s, 6-
H), 7.37-7.48 (6 H, m, ArH) and 7.73-7.76 (4 H, m, ArH); δC (75 
MHz, CDCl3) 15.2, 19.6, 27.2, 37.7, 67.0, 113.9, 126.7, 128.0, 
129.9, 133.8, 135.8, 140.3, 155.6, 157.7 and 164.6; m/z (ES+) 446.4 
(M+ + 1, 100%). 
 
2-Dimethylamino-5-hydroxymethyl-7-methyloxazolo[4,5-
b]pyridine (25) 
Tetrabutylammonium fluoride in tetrahydrofuran (1 M, 0.7 mL, 0.70 
mmol, 1.2 eq) was added to the silyl ether 24 (260 mg, 0.58 mmol) 
in tetrahydrofuran (10 mL) at rt and the solution stirred for 1 h. After 
concentration under reduced pressure, chromatography of the residue 
10% MeOH/CH2Cl2) gave the title compound 25 as a white solid 
(111 mg, 92%), Rf 0.24 (10% MeOH/Et2O), m.p. 203-205 °C 
(Found: M+ + H, 208.1084. C10H14N3O2 requires M, 208.1081); 
Ȟmax/cm-1 3235, 2925, 2873, 1662, 1644, 1574, 1403, 1383, 1136, 
1064, 895, 837, 776 and 726ν δH (300 MHz, CD3OD) 2.47 (3 H, s, 7-
CH3), 3.26 [6 H, s, 2-N(CH3)2], 4.65 (2 H, s, 5-CH2) and 7.00 (1 H, 
s, 6-H)ν δC (75 MHz, CD3OD) 13.5, 36.5, 64.5, 114.6, 127.8, 140.3, 
155.3, 157.2 and 164.8; m/z (ES+) 437.0 (2M+ + 23, 20%), 230.1 
(M+ + 23, 22) and 208.2 (M+ + 1, 100%).   
 
N-(2-Dimethylamino-7-methyloxazolo[4,5-b]pyridin-5-ylmethyl) 
2-nitrobenzenesulfonamide (26) 
Di-isopropylazodicarboxylate (104 µL, 0.53 mmol, 1.3 eq) was 
added to 2-nitrobenzenesulfonamide (123 mg, 0.61 mmol, 1.5 eq), 
triphenylphosphine (139 mg, 0.53 mmol, 1.3 eq) and the alcohol 25 
(84.2 mg, 0.41 mmol) in tetrahydrofuran (10 mL) and the reaction 
mixture stirred at rt for 16 h. After concentration under reduced 
pressure, chromatography of the residue (Et2O to 10% MeOH/Et2O) 
gave the title compound 26 (50 mg, 31%), Rf 0.36 (10% 
MeOH/Et2O) (Found: M+ + H, 392.1027. C16H18N5O5S requires M, 
392.1023); Ȟmax/cm-1 3330, 3094, 3031, 1664, 1572, 1540, 1430, 
1393, 1372, 1341, 1291, 1167, 895, 854, 782 and 733; δH (300 MHz, 
CDCl3) 2.38 (3 H, s, 7-CH3), 3.26 [6 H, s, 2-N(CH3)2], 4.38 (2 H, d, 
J 5.4 Hz, 5-CH2), 6.43 (1 H, m, NH), 6.73 (1 H, s, 6-H), 7.64-7.71 (2 
H, m, ArH), 7.84 (1 H, m, ArH) and 8.13 (1 H, m, ArH); δC (75 
MHz, CDCl3) 14.9, 37.8, 48.7, 116.1, 125.4, 127.0, 131.1, 132.7, 
133.5, 133.9, 140.6, 148.2, 149.5, 158.1, 164.8; m/z (ES+) 450.3 
(85%), 414.2 (M+ + 23, 18) and 392.2 (M+ + 1, 100). The bis-
alkylated sulfonamide, bis-N-(2-dimethylamino-7-
methyloxazolo[4,5-b]pyridin-5-ylmethyl) 2-nitrobenzene-
sulfonamide was also isolated (Found: M+ + H, 581.1917. 
C26H29N8O6S requires M, 581.1925); Ȟmax/cm-1 3417, 2960, 2928, 
1729, 1664, 1568, 1543, 1390, 1287, 1163, 1075, 894, 791 and 734; 
δH (300 MHz, CDCl3) 2.34 (6 H, s, 2  7-CH3), 3.27 [12 H, s, 2  2-
N(CH3)2], 4.79 (4 H, s, 2  5-CH2), 6.83 (2 H, s, 2  6-H), 7.50-7.64 
(3 H, m, ArH) and 8.15 (1 H, m, ArH); m/z (ES+) 581.4 (M+ + 1, 
100%). 
 
5-Aminomethyl-2-dimethylamino-7-methyloxazolo[4,5-
b]pyridine (5) 
A mixture of the sulfonamide 26 (50 mg, 0.13 mmol), thiophenol 
(039 µL, 0.38 mmol, 3.0 eq) and potassium carbonate (70 mg, 0.51 
mmol) in acetonitrile (2.1 mL) was stirred at rt for 16 h. Direct 
chromatography (10% to 20% MeOH/CH2Cl2/1% Et3N) gave the 
title compound 5 as a pale oil (22 mg, 84%), Rf 0.57 (20% 
MeOH/CH2Cl2) (Found: M+ + H, 207.1232. C8H13N7 requires M, 
207.1227)ν Ȟmax/cm-1 3368, 2928, 1667, 1572, 1431, 1394, 1288, 
1220, 1142, 896 and 733ν δH (300 MHz, CD3OD) 2.46 (3 H, s, 7-
CH3), 3.27 [6 H, s, 2-N(CH3)2], 3.93 (2 H, br s, 5-CH2) and 6.88 (1 
H, s, 6-H)ν δC (75 MHz, CD3OD) 13.4, 36.6, 45.3, 115.8, 127.8, 
140.5, 153.0, 157.5 and 164.8;  m/z (ES+) 207.2 (M+ + 1, 100%). 
 
1-[6-(2-Dimethylamino-7-methyloxazolo[4,5-b]pyridin-5-
ylmethylamino)-9H-purin-9-yl]-2,3-O-isopropylidene-1-deoxy-
N-methyl--D-ribofuranuronamide (27) 
A solution of 6-chloropurine-2,3-O-isopropylidene-N-
methyluronamide 4 (38 mg, 0.11 mmol), amine 5 (22 mg, 0.11 
mmol) and triethylamine (30 µL, 0.21 mmol, 2.0 eq) in ethanol (1.1 
mL) was stirred at 80 °C for 16 h then comcentrated under reduced 
pressure. Chromatography of the residue (20% to 30% 
MeOH/Et2O/1% Et3N) gave the title compound 27 as a white solid 
(51 mg, 90%), Rf 0.27 (20% MeOH/Et2O), m.p. >250 °C (dec.) 
(Found: M+ + Na, 546.2178. C24H29N9O5Na requires M, 546.2184); 
Ȟmax/cm-1 3380, 2986, 2939, 1652, 1644, 1621, 1615, 1574, 1480, 
1430, 1393, 1333, 1290, 1266, 1213, 1157, 1092, 977, 895, 869, 
851, 797 and 734; δH (500 MHz, CD3OD) 1.27 and 1.44 (each 3 H, 
s, CH3), 2.19 (3 H, s, NHCH3), 2.20 (3 H, s,  7-CH3), 3.08 [6 H, s, 
2-N(CH3)2], 4.50 (1 H, d, J 1.0 Hz, 4-H), 4.68 (2 H, br. s, 5-CH2), 
5.32 (1 H, dd, J 6.0, 1.0 Hz, 2-H), 5.44 (1 H, dd, J 6.0, 2.0 Hz, 3-
H), 6.19 (1 H, d, J 1.0 Hz, 1-H), 6.69 (1 H, s, 6-H), 8.06 (1 H, s, 8-
H) and 8.07 (1 H, s, 2-H); δC (75 MHz, CD3OD) 8.14, 13.5, 24.3, 
24.7, 26.0, 36.6, 84.0, 84.2, 87.4, 91.4, 113.8, 115.2, 119.7, 127.6, 
140.2, 141.0, 147.7, 152.5, 152.7, 154.8, 157.5, 164.8 and 171.1; m/z 
(ES+) 655.8 (100%), 562.7 (M+ + 39, 2) and 546.6 (M+ + 23, 26). 
 
1-[6-(2-Dimethylamino-7-methyloxazolo[4,5-b]pyridin-5-
ylmethylamino)-9H-purin-9-yl]-1-deoxy-N-methyl--D-
ribofuranuronamide  (3) 
A solution of the acetonide 27 (51 mg, 0.10 mmol) in aqueous 
hydrogen chloride (1 M, 793 µL) was stirred at 65 °C for 1 h. After 
cooling, saturated aqueous sodium hydrogen carbonate was added 
until pH 7 and the mixture was concentrated under reduced pressure. 
Chromatography of the residue (CH2Cl2 to 10% MeOH/CH2Cl2/1% 
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Et3N) gave the title compound 3 as a white solid (35 mg, 76%), Rf  
0.17 (20% MeOH/Et2O), m.p. >228 °C (dec.) (Found:  M+ + H, 
484.2055. C21H26N9O5 requires M, 484.2051); Ȟmax/cm-1 3336, 3241, 
3086, 2938, 1660, 1618, 1573, 1483, 1399, 1385, 1371, 1330, 1294, 
1283, 1232, 1226, 1192, 1136, 1099, 1050, 898, 851, 797, 745 and 
732; δH (500 MHz, DMSO-d6) 2.38 (3 H, s, 7-CH3), 2.78 (3 H, d, J 
4.8 Hz, NHCH3), 3.21 [6 H, s, 2-N(CH3)2], 4.21 (1 H, td, J 4.3, 1.3 
Hz, 3-H), 4.38 (1 H, d, J 0.8 Hz, 4-H), 4.67 (1 H, td, J 6.9, 4.8 Hz, 
2-H), 4.80 (2 H, br. d, J 5.0 Hz, 5-CH2), 5.67 (1 H, d, J 6.3 Hz, 2-
OH), 5.84 (1 H, d, J 4.3 Hz, 3-OH), 6.05 (1 H, d, J 7.6 Hz, 1-H), 
6.81 (1 H, s, 6-H), 8.35 (1 H, s, 2-H), 8.47 (1 H, br. t, J 5.0 Hz, 6-
NH), 8.53 (1 H, s, 8-H) and 9.01 (1 H, q, J 4.5 Hz, NHCO); δC (100 
MHz, DMSO-d6) 14.3, 25.3, 37.0, 44.6, 72.0, 73.1, 84.7, 87.8, 113.9, 
120.1, 126.1, 139.3, 140.7, 148.1, 152.5, 153.0, 154.6, 157.2, 164.0 
and 169.8; m/z (ES+) 506.2 (M+ + 23, 3%) and 484.3 (M+ + 1, 100). 
 
5-tert-Butyldiphenylsilyloxymethyl-7-methyloxazolo[4,5-
b]pyridine-2(3H)-thione (28)  
Carbon disulfide (0.468 mL, 7.7 mmol) was added to the 
aminopyridine 23 (200 mg, 0.509 mmol) and potassium hydroxide 
(65 mg, 1.16 mmol) in ethanol (1.42 mL) at rt and the mixture 
heated under reflux for 3 h then concentrated under reduced 
pressure. The residue was partitioned between aqueous hydrogen 
chloride (5 M, 10 mL) and ethyl acetate (4  15 mL), and the organic 
extracts were dried (MgSO4) then concentrated under reduced 
pressure to yield the title compound 28 a yellow solid (184 mg, 83 
%), Rf 0.37 (50 % Et2O/light petroleum), m.p. 166.4-168.2 °C 
(Found: M+ + H, 435.1550. C24H27O2N2SSi requires M, 435.1557); 
Ȟmax/cm-1 3070, 2930, 2857, 1654, 1613, 1488, 1449, 1427, 1391, 
1378, 1289, 1269, 1180, 1114, 906, 835, 822, 739 and 701ν δH (300 
MHz, CDCl3) 1.20 [9 H, s, SiCCH3)3], 2.53 (3 H, s, 7-CH3), 5.19 (2 
H, s, 5-CH2), 7.36-7.51 (7 H, m, ArH) and 7.71-7.77 (4 H, m, ArH); 
δC (75 MHz, CDCl3) 15.3, 19.6, 27.3, 66.5, 117.7, 128.1, 130.2, 
130.8, 133.2, 135.9, 140.8, 145.7, 156.6 and 181.1; m/z (ES) 433.5 
(M+  1, 100 %). 
 
5-tert-Butyldiphenylsiloxymethyl-2-diethylamino-7-
methyloxazolo[4,5-b]pyridine (30)  
Thionyl chloride (12.6 ȝL, 0.15 mmol) was added to a suspension of 
the thione 28 (50 mg, 0.1 mmol) and sodium carbonate (18 mg, 0.15 
mmol) in benzene (0.13 mL) at 0 ºC and the reaction mixture 
warmed to 50 °C for 3 h then allowed to cool to rt. Diethylamine (66 
ȝL, 0.55 mmol) was added dropwise and the reaction mixture stirred 
at rt for 1 h. The mixture was partitioned between water (10 mL) and 
Et2O (4  15 mL). The organic extracts were dried (Na2SO4) then 
concentrated under reduced pressure. Chromatography of the residue 
(Et2O to10 % MeOH/Et2O) gave the title compound 30 as a pale oil 
which solidified upon storage (37 mg, 70 %), Rf 0.38 (50 % Et2O/ 
light petroleum), m.p. 90.3-91.6 °C (Found: M+ + H, 474.2567. 
C28H36O2N3Si requires M, 474.2571); Ȟmax/cm-1 3067, 2959, 2929, 
2890, 2855, 2355, 1655, 1565, 1461, 1445, 1427, 1389, 1361, 1138, 
1112, 1082, 968, 822 and 700ν δH (300 MHz, CDCl3) 1.19 [9 H, s, 
Si(CH3)3], 1.33 (6 H, t, J 7.1 Hz, 2  NCH2CH3), 2.49 (3 H, s, 7-
CH3), 3.65 (4 H, q, J 7.1 Hz, 2  NCH2CH3), 4.92 (2 H, s, 5-CH2), 
7.13 (1 H, s, 6-H), 7.35-7.47 (6 H, m, ArH) and 7.74-7.79 (4 H, m, 
ArH)ν δC (75 MHz, CDCl3) 13.7, 15.3, 19.6, 27.2, 43.2, 67.0, 113.7, 
126.5, 128.0, 129.9, 133.8, 135.8, 140.0, 155.5, 157.8 and 163.9; m/z 
(ES+) 947.6 (2M+ + 1, 24 %) and 474.4 (M+ + 1, 100). 
 
2-Diethylamino-5-hydroxymethyl-7-methyloxazolo[4,5-
b]pyridine (31)  
Tetrabutylammonium fluoride in tetrahydrofuran (1 M, 0.8 mL, 0.77 
mmol) was added to the silyl ether 30 (303 mg, 0.64 mmol) in 
tetrahydrofuran (10.7 mL) and the reaction mixture stirred for 1 h at 
rt. After concentration under reduced pressure, the residue was 
partitioned between water (20 mL) and Et2O (4  20 mL). The 
organic extracts were dried (Na2SO4) and concntrated under reduced 
pressure. Chromatography of the residue (Et2O to10 % MeOH/Et2O) 
gave the title compound 31 as a pale oil (139 mg, 93 %), Rf 0.45 (10 
% MeOH/Et2O) (Found: M+ + H, 236.1396. C12H18O2N3 requires M, 
236.1394); Ȟmax/cm-1 3309, 2974, 2934, 2360, 2340, 1650, 1636, 
1570, 1448, 1388, 1363, 1205, 1137, 1071, 968, 876, 778, and 734; 
δH (500 MHz, CDCl3) 1.23 (6 H, t, J 7.3 Hz, 2  NCH2CH3), 2.32 (3 
H, s, 7-CH3), 3.55 (4 H, q, J 7.3 Hz, 2  NCH2CH3), 4.61 (2 H, s, 5-
CH2) and 6.57 (1 H, s, 6-H)ν δC (125 MHz, CDCl3) 13.4, 14.7, 43.0, 
64.1, 113.7, 126.8, 139.8, 153.7, 157.3 and 163.6; m/z (ES+) 236.2 
(M+ + 1, 100%). 
 
N-(2-Diethylamino-7-methyloxazolo[4,5-b]pyridin-5-yl)methyl-
N-tert-butoxcarbonyl 2-nitrophenylsulfonamide (33)  
Di-isopropylazo dicarboxylate (22 ȝL, 0.11 mmol) was added to the 
alcohol 31 (20 mg, 0.087 mmol), sulfonamide 32 (39 mg, 0.13 
mmol) and triphenylphosphine (29 mg, 0.11 mmol) in 
tetrahydrofuran (2.2 mL) at rt and the reaction mixture stirred for 16 
h. After concentration under reduced presssure, chromatography of 
the residue (Et2O) gave the title compound 33 as a pale oil (44 mg, 
98 %), Rf 0.24 (Et2O) (Found:  M+ + H, 520.1860. C23H30O7N5S 
requires M, 520.1860); Ȟmax/cm-1 2979, 1735, 1652, 1640, 1565, 
1544, 1365, 1149 and 1123ν δH (300 MHz, CDCl3) 1.30 [9 H, s, 
C(CH3)3], 1.33 (6 H, t, J 7.2 Hz,  2  NCH2CH3), 2.44 (3 H, s, 7-
CH3), 3.67 (4 H, q, J 7.2 Hz, 2  NCH2CH3), 5.11 (2 H, s, 5-CH2), 
6.87 (1 H, s, 6-H), 7.76-7.84 (3 H, m, ArH) and 8.52-8.60 (1 H, m, 
ArH)ν δC (75 MHz, CDCl3) 13.7, 15.1, 28.0, 43.2, 52.5, 85.2, 114.1, 
124.6, 126.6, 132.1, 133.7, 133.9, 134.3, 140.1, 148.1, 150.8, 151.7, 
158.1 and 164.0; m/z (ES+) 1061.5 (2M+ + 23, 80 %), 542.3 (M+ + 
23, 78) and 520.4 (M+ + 1, 100%). 
 
N-(2-Diethylamino-7-methyloxazolo[4,5-b]pyridin-5-yl)methyl 2-
nitrobenzenesulfonamide (34)  
Sulfonamide 33 (102 mg, 0.2 mmol) was dissolved in trifluoroacetic 
acid (0.51 mL) and the solution stirred at rt for 1 h. Ethyl acetate was 
added and the mixture was partitioned between saturated aqueous 
sodium bicarbonate (5 mL) and Et2O (5 x 50 mL). The organic 
extracts were dried (MgSO4) and concentrated under reduced 
pressure. Chromatography of the residue (Et2O to 10 % 
MeOH/Et2O) gave the title compound 34 as a pale yellow oil (64 
mg, 79 %) Rf 0.1 (Et2O) (Found: M+ + H, 420.1330. C18H22O5N5S 
requires M, 420.1336); Ȟmax/cm-1 2978, 2360, 1655, 1640, 1568, 
1540, 1445, 1393, 1363, 1207, 1167, 1081, 970, 853, 785 and 734; 
δH (300 MHz, CDCl3) 1.32 (6 H, t, J 7.2 Hz, 2  NCH2CH3), 2.39 (3 
H, s, 7-CH3), 3.64 (4 H, q, J 7.2 Hz, 2  NCH2CH3), 4.38 (2 H, d, J 
2.7 Hz, 5-CH2), 6.41 (1 H, br. t, J 2.7 Hz, NH), 6.72 (1 H, s, 6-H), 
7.63-7.71 (2 H, m, ArH), 7.85 (1 H, m, ArH) and 8.10 (1 H, m, 
ArH)ν δC (75 MHz, CDCl3) 13.6, 14.9, 43.3, 48.8, 115.9, 125.5, 
126.7, 131.1, 132.6, 133.4, 134.1, 140.3, 149.4, 158.2 and 164.0; m/z 
(ES+) 839.4 (2M+ + 1, 30 %), 442.3 (M+ + 23, 37 ) and 420.3 (M+ + 
1, 100). 
 
5-Aminomethyl-2-diethylamino-7-methyloxazolo[4,5-b]pyridine 
(35)  
Thiophenol (17 ȝL, 0.25 mmol) was added to a suspension of the 
sulfonamide 34 (24 mg, 0.084 mmol) and potassium carbonate (31 
mg, 0.34 mmol) in acetonitrile (0.95 mL) at rt and the reaction 
mixture was stirred for 16 h. After concentration under reduced 
pressure, chromatography of the residue (10 % MeOH/CH2Cl2 
containing 1 % NEt3) gave the title compound 35 as a pale yellow oil 
(12 mg, 85 %), Rf 0.1 (10 % MeOH/Et2O) (Found: M+ + H, 
235.1558. C12H19ON4 requires M, 235.1553); Ȟmax/cm-1 3369, 2976, 
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1651, 1567, 1448, 1392, 1364, 1319, 1209, 1083, 1027, 877, 786 and 
732ν δH (300 MHz, CDCl3) 1.29 (6 H, t, J 7.2 Hz, 2  NCH2CH3), 
2.38 (3 H, s, 7-CH3), 3.62 (4 H, q, J 7.2 Hz, 2  NCH2CH3), 4.22 (2 
H, s, 5-CH2), 5.28 (2 H, br. s, NH2) and 6.77 (1 H, s, 6-H)ν δC (75 
MHz, CDCl3) 13.6, 14.9, 43.3, 47.0, 115.2, 126.7, 140.0, 155.0, 
158.2 and 163.8; m/z (ES+) 257.2 (M+ + 23, 52 %) and 235.2 (M+ + 
1, 100).  
 
1-[6-(2-Diethylamino-7-methyloxazolo[4,5-b]pyridin-5-
ylmethylamino)-9H-purin-9-yl]-1-deoxy-N-methyl--D-
ribofuranuronamide (37)  
The chloropurine 4 (17 mg, 0.049 mmol) was added to the amine 35 
(12 mg, 0.049 mmol) and triethylamine (13.7 ȝL, 0.1 mmol) in 
ethanol (0.5 mL) and the reaction mixture heated under reflux for 16 
h. Concentration by distillation under reduced pressure gave the 
2,3-O-isopropylidene-1-deoxy-N-methyl--D-ribofuranuronamide 
36 as an oil (15 mg, 55 %), Rf 0.41 (10 % MeOH/ Et2O) (Found: M+ 
+ H, 552.2684. C26H34N9O5 requires M, 552.2677); δH (500 MHz, 
CDCl3) 1.24 (6 H, t, J 7.0 Hz, 2  NCH2CH3), 1.32 and 1.54 (each 3 
H, s, CH3), 2.31 (3 H, s,  7-CH3), 2.53 (3 H, d, J 3.0 Hz, NHCH3), 
3.55 (4 H, q, J 7.0 Hz, 2  NCH2CH3), 4.62 (1 H, s, 4-H), 4.80 (2 H, 
m, 5-CH2), 5.28 (2 H, m, 2-H and 3-H), 5.98  (1 H, s, 1-H), 6.69 
(1 H, s, 6-H), 7.10 (1 H, br. s, 6-NH), 7.22 (1 H, br. s, NHCH3), 
7.73 (1 H, s, 2-H) and 8.27 (1 H, br. s, 8-H); δC (125 MHz, CDCl3) 
13.4, 14.7, 25.1, 25.6, 27.1, 30.3, 43.1, 45.3, 82.5, 83.7, 85.8, 92.1, 
114.4, 115.4, 120.8, 126.6, 139.3, 140.0, 151.0, 153.2, 154.9, 157.9, 
163.6 and 169.5; m/z (ES+) 574.4 ((M+ + 23, 100%) and 552.7 (20). 
This was immediately dissolved in aqueous hydrogen chloride (1 M, 
1.5 mL) and the mixture stirred at 65 °C for 1 h. The mixture was 
neutralised to pH 7 using saturated aqueous sodium hydrogen 
carbonate then concentrated under reduced pressure. 
Chromatography of the residue (CH2Cl2 to 20 % MeOH/CH2Cl2) 
gave the title compound 37 as a white solid (12 mg, 46 %), Rf 0.1 
(20 % MeOH/DCM) (Found: M+ + H, 512.2373. C23H30O5N9 
requires M, 512.2364)ν δH (500 MHz, DMSO-d6) 1.23 (6 H, t, J 6.9 
Hz, 2  NCH2CH3), 2.33 (3 H, s, 7-CH3), 2.73 (3 H, d, J 4.4 Hz, 
NHCH3), 3.57 (4 H, q, J 6.9 Hz, 2  NCH2CH3), 4.16 (1 H, m, 3-H), 
4.33 (1 H, s, 4-H), 4.62 (1 H, m, 2-H), 4.74 (2 H, d, J 4.7 Hz, 5-
CH2), 5.61 (1 H, d, J 6.3 Hz, 2-OH), 5.78 (1 H, d, J 4.4 Hz, 3-OH), 
6.00 (1 H, d, J 7.5 Hz, 1-H), 6.76 (1 H, s, 6-H), 8.30 (1 H, s, 2-H), 
8.42 (1 H, br s, 6-NH), 8.47 (1 H, s, 8-H) and 8.96 (1 H, m, 
NHCH3); m/z (ES+) 533.8 (M+ + 23, 85 %) and 512.2 (M+ + 1, 100). 
 
(±)-5-[(E)-tert-Butylsulfinyliminomethyl]-2-dimethylamino-7-
methyloxazolo[4,5-b]pyridine (40)  
Dess-Martin periodinane (399 mg, 0.94 mmol) was added to the 
alcohol 25 (130 mg, 0.63 mmol) in dichloromethane (4.5 mL) and 
the solution stirred for 20 min at rt. The reaction mixture was 
concentrated under reduced pressure to give an oil, Rf 0.36 (10 % 
MeOH/Et2O), that was dissolved in dichloromethane (1.6 mL). 
Anhydrous copper sulphate (200 mg, 1.25 mmol) and racemic tert-
butanesulfinamide (84 mg, 0.69 mmol) were added and the mixture 
was stirred at rt for 16 h. The reaction mixture was then filtered and 
the filtrate concentrated under reduced pressure. Chromatography of 
the residue (0.5% to 2 % MeOH/CH2Cl2) gave the title compound 40 
as a pale oil (135 mg, 70 %), Rf 0.43 (10 % MeOH/Et2O) (Found: 
M+ + Na, 331.1195. C14H20O2N4NaS requires M, 331.1199); 
Ȟmax/cm-1 2927, 1664, 1600, 1558, 1430, 1393, 1285, 1188, 1138, 
1085, 891, 772 and 732ν δH (500 MHz, CDCl3) 1.21 [9 H, s, 
C(CH3)3], 2.40 (3 H, s, 7-CH3), 3.21 (6 H, s, 2  NCH3), 7.47 (1 H, 
s, 6-H) and 8.57 (1 H, s, 5-CH)ν δC (125 MHz, CDCl3) 14.7, 22.1, 
22.7, 57.8, 118.7, 126.4, 142.7, 147.6, 158.6 and 164.0; m/z (ES+) 
331 (M+ + 23, 100 %). 
 
(±)-5-[(E)-tert-Butylsulfinyliminomethyl]-2-diethylamino-7-
methyl-oxazolo[4,5-b]pyridine (41)  
Following the procedure outlined for the synthesis of imine 40, 
alcohol 31 (116 mg, 0.5 mmol) in dichloromethane (3.5 mL) and the 
Dess-Martin periodinane (315 mg, 0.74 mmol) gave the aldehyde 39, 
Rf 0.5 10 % MeOH. This aldehyde without purification, in 
dichloromethane (1.24 mL), anhydrous copper sulphate (158 mg, 
0.99 mmol) and racemic tert-butanesulfinamide (66 mg, 0.54 mmol), 
after chromatography (0.5% to 2 % MeOH/CH2Cl2) gave the title 
compound 41 as a pale yellow oil (150 mg, 90 %), Rf 0.57 (10 % 
MeOH/Et2O) (Found: M+ + H, 337.1704 C16H25O2N4S requires M, 
337.1693); Ȟmax/cm-1 3434, 2971, 2361, 1647, 1601, 1553, 1450, 
1393, 1210, 1138, 1084, 872 and 769ν δH (500 MHz, CDCl3) 1.21 [9 
H, s, C(CH3)3], 1.24 (6 H, t, J 7.2 Hz, 2  NCH2CH3), 2.40 (3 H, s, 
7-CH3), 3.58 (4 H, q, J 7.2 Hz,  2  NCH2CH3), 7.45 (1 H, s, 6-H) 
and 8.56 (1 H, s, 5-CH)ν δC (75 MHz, CDCl3) 13.6, 15.0, 22.9, 43.4, 
58.1, 118.8, 126.5, 142.7, 147.7, 158.9 and 164.2; m/z (ES+) 337.2 
(M+ + 1, 100 %). 
 
5-{(RS)-1-[(RS)-tert-Butylsulfinylamino]ethyl}-2-dimethylamino-
7-methyloxazolo[4,5-b]pyridine  (42)  
Methylmagnesium bromide in ether (3 M, 0.51 mL, 1.6 mmol) was 
added dropwise to the sulfinimine 40 (132 mg, 0.43 mmol) in 
tetrahydrofuran (4.3 mL) at –78 ºC. The reaction mixture was stirred 
at -78 °C for 1 h and then saturated aqueous ammonium chloride (5 
mL) was added. The mixture was extracted with ethyl acetate (6  5 
mL) and the organic extracts were dried (Na2SO4) and concentrated 
under reduced pressure. Chromatography of the residue (CH2Cl2 to 
4% MeOH/CH2Cl2) gave the title compound 42 as a pale oil (119 
mg, 76 %), Rf 0.1 (EtOAc) (Found: M+ + H, 325.1691. C15H25O2N4S 
requires M, 325.1693); Ȟmax/cm-1 3234, 2927, 1667, 1570, 1430, 
1389, 1290, 1190, 1145, 1063 and 894ν δH (500 MHz, CDCl3) 1.16 
[9 H, s, C(CH3)3], 1.42 (3 H, d, J 6.6 Hz, 5-CHCH3), 2.31 (3 H, s, 7-
CH3), 3.16 (6 H, s, 2  NCH3), 4.42 (1 H, quin, J 6.6 Hz, 5-CH), 
4.51 (1 H, d, J 6.3 Hz, NH) and 6.64 (1 H, s, 6-H)ν δC (75 MHz, 
CDCl3) 15.0, 22.4, 23.0, 24.2, 37.7, 56.4, 115.2, 126.9, 140.4, 157.4, 
158.0 and 164.7; m/z (ES+) 325 (M+ + 1, 100 %). 
 
5-{(RS)-1-[(RS)-tert-Butylsulfinylamino]ethyl}-2-diethylamino-7-
methyloxazolo[4,5-b]pyridine (43)  
Following the procedure outlined for the synthesis of amine 42, the 
sulfinimine 41 (150 mg, 0.45 mmol) in tetrahydrofuran (4.45 mL) 
and methylmagnesium bromide in ether (3 M, 0.53 mL, 1.6 mmol), 
after chromatography (CH2Cl2 to 4 % MeOH/CH2Cl2), gave the title 
compound 43 as a pale yellow oil (119 mg, 76 %), Rf 0.1 (EtOAc) 
(Found: M+ + Na, 375.1834. C17H28O2N4NaS requires M, 375.1825); 
Ȟmax/cm-1 2974, 1654, 1565, 1388 and 1069ν δH (500 MHz, CDCl3) 
1.15 [9 H, s, C(CH3)3], 1.22 (6 H, t, J 7.2 Hz, 2  NCH2CH3), 1.43 
(3 H, d, J 6.6 Hz, 5-CHCH3), 2.31 (3 H, s, 7-CH3), 3.55 (4 H, q, J 
7.2 Hz, 2  NCH2CH3), 4.40 (1 H, quin, J 6.7 Hz, 5-CH), 4.49 (1 H, 
d, J 6.9 Hz, NH) and 6.62 (1 H, s, 6-H)ν δC NMR (125 MHz, CDCl3) 
12.4, 13.7, 21.7, 22.9, 42.0, 54.6, 55.4, 113.7, 125.4, 138.9, 156.0, 
156.9 and 162.6; m/z (ES+) 374.9 (M+ + 23, 100 %). 
 
(±)-5-(1-Aminoethyl)-2-dimethylamino-7-methyloxazolo[4,5-
b]pyridine (44)  
Hydrogen chloride in dioxane (4 M, 0.61 mL, 2.4 mmol) was added 
to the sulfinamide 42 (132 mg, 0.407 mmol) in MeOH (4.1 mL) and 
the reaction mixture was stirred at rt for 30 min. Saturated aqueous 
sodium bicarbonate was added until the mixture was basic. After 
concentration under reduced pressure, chromatography of the residue 
(CH2Cl2 to 3% MeOH/CH2Cl2 with 0.5% NEt3) gave the title 
compound 44 as a pale waxy solid (74 mg, 83 %), Rf 0.3 (10 %/ 
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MeOH/DCM) (Found: M+ + H, 221.1397. C11H17ON4 requires M, 
221.1397); Ȟmax/cm-1 3365, 2920, 2361, 1659, 1572, 1431, 1392, 896 
and 734ν δH (300 Mz, CDCl3) 1.49 (3 H, d, J 6.6 Hz, 5-CHCH3), 
2.41 (3 H, s, 7-CH3), 3.01 (2 H, br. s, NH2), 3.27 (6 H, s, 2  NCH3), 
4.15 (1 H, br. q, J 6.7 Hz, 5-CH) and 6.72 (1 H, s, 6-H)ν δC (75 MHz 
CDCl3) 15.0, 24.5, 37.7, 52.4, 114.4, 126.8, 140.2, 157.9, 159.8 and 
164.6; m/z (ES+) 441.5 (2M+ + 1, 16 %) and 221.1 (M+ + 1, 100). 
 
(±)-5-(1-Aminoethyl)-2-diethylamino-7-methyloxazolo[4,5-
b]pyridine (45)  
Following the procedure outlined for the synthesis of amine 44, 
sulfinamide 43 (110 mg, 0.313 mmol) in MeOH (3.1 mL) and 
hydrogen chloride in dioxane (4 M, 0.47 mL, 1.88 mmol), after 
chromatography (CH2Cl2 to 3% MeOH/CH2Cl2 with 0.5 % NEt3) 
gave the title compound 45 as a pale oil (64 mg, 82 %), Rf 0.2 (10%/ 
MeOH/CH2Cl2) (Found: M+ + H, 249.1705. C13H21ON4 requires M, 
249.1710); Ȟmax/cm-1 3356, 2973, 1652, 1565, 1447, 1387 and 1081; 
δH (500 MHz, CDCl3) 1.21 (6 H, t, J 7.1 Hz, 2  NCH2CH3), 1.41 (3 
H, d, J 6.6 Hz, 5-CHCH3), 2.32 (3 H, s, 7-CH3), 3.12 (2 H, br. s, 
NH2), 3.55 (4 H, q, J 7.1 Hz, 2  NCH2CH3), 4.08 (1 H, br. q, J 6.3 
Hz, 5-CH) and 6.61 (1 H, s, 6-H)ν δC (75 MHz, CDCl3) 13.4, 14.7, 
24.7, 42.9, 52.3, 113.7, 126.2, 139.5, 157.9, 160.5 and 163.6; m/z 
(ES+) 249 (M+ + 1, 100 %). 
 
1-{6-[(RS)-1-(2-Dimethylamino-7-methyloxazolo[4,5-b]pyridin-
5-yl)ethylamino]-9H-purin-9-yl}-1-deoxy-N-methyl--D-
ribofuranuronamide (48)  
The chloropurine 4 (111 mg, 0.313 mmol) was added to the amine 
44 (69 mg, 0.313 mmol) and triethylamine (87 ȝL, 0.626 mmol) in 
ethanol (3.1 mL) and the reaction mixture was stirred under reflux 
for 16 h. Concentration under reduced pressure gave 2,3-O-
isopropylidene-1-deoxy-N-methyl--D-ribofuranuronamide 46 as a 
pale oil, Rf 0.38 (20% MeOH/Et2O) (Found: M+ + H, 538.2523. 
C25H32N9O5 requires M, 538.2521); m/z (ES+) 538.1 (M++ 1, 100 
%). This was immediately dissolved in aqueous hydrogen chloride (1 
M, 1.5 mL). The reaction mixture stirred at 65 °C for 1 h and 
saturated aqueous sodium bicarbonate was added until the reaction 
mixture was neutral. After concentration under reduced pressure, 
chromatography of the residue (CH2Cl2 to 20% MeOH/CH2Cl2) gave 
the title compound 48 as a white solid (77 mg, 50 %), Rf 0.6 (20% 
MeOH/DCM), m.p. 171-173 °C (Found: M+ + H, 498.2206. 
C22H28O5N9 requires M, 498.2208)ν δH (500 MHz, DMSO-d6) 1.55 
(3 H, d, J 6.9 Hz, 5-CHCH3), 2.35 (3 H, s, 7-CH3), 2.71 (3 H, m, 
NHCH3), 3.17 (6 H, s, 2  NCH3), 4.16 (1 H, m, 3-H), 4.32 (1 H, s, 
4-H), 4.61 (1 H, m, 2-H), 5.47 (1 H, m, 5-CH), 5.54 (1 H, br. d, J 
6.0 Hz, 2-OH), 5.72 (1 H, d, J 4.5 Hz, 3-OH), 5.98 (1 H, d, J 7.3 
Hz, 1-H), 6.91 (1 H, s, 6-H), 8.10 (1 H, m, 6-NH), 8.29 (1 H, s, 2-
H), 8.46 (1 H, s, 8-H), 8.87 (1 H, m, NHCH3); m/z (ES+) 995.5 (2M+ 
+ 1, 17 %) and 498.4 (M+ + 1, 100). 
 
1-{6-[(RS)-1-(2-Diethylamino-7-methyloxazolo[4,5-b]pyridin-5-
yl)ethylamino]-9H-purin-9-yl}-1-deoxy-N-methyl--D-
ribofuranuronamide (49)  
Following the procedure outlined for the synthesis of the adenosine 
uronamide 48, the amine 45 (64 mg, 0.258 mmol) and triethylamine 
(72 ȝL, 0.52 mmol) in ethanol (2.6 mL) together with the 
chloropurine 4 (92 mg, 0.258 mmol) gave the 2,3-O-
isopropylidene-1-deoxy-N-methyl--D-ribofuranuronamide 47 as a 
pale oil (120 mg, 82 %), Rf 0.25 (10% MeOH/Et2O) (Found: M+ + 
Na, 588.2645. C27H35N9O5Na requires M, 588.2653); Ȟmax/cm-1 
3348, 2977, 1654, 1613, 1565, 1381, 1213, 1088, 871, 756 and 733; 
δH (500 MHz, CDCl3) 1.25 (6 H, t, J 7.0 Hz, 2  NCH2CH3), 1.30 
and 1.54 (each 3 H, s, CH3), 1.54 (3 H, d, J 4.5 Hz, 5-CHCH3), 2.33 
(3 H, s,  7-CH3), 2.57 (3 H, narrow m, NHCH3), 3.57 (4 H, m, 2 x 
NCH2CH3), 4.61 (1 H, s, 4-H), 5.24 (2 H, m, 2-H and 3-H), 5.44 (1 
H, m, 5-H), 5.95 (1 H, s, 1-H), 6.69 (1 H, s, 6-H), 7.01 and 7.22 
(each 1 H, m, NH), 7.69 (1 H, s, 2-H) and 8.23 (1 H, s, 8-H); δC (75 
MHz, CDCl3) 13.6, 15.0, 23.1, 25.4, 25.8, 27.4, 43.3, 51.0, 82.7, 
83.9, 85.9, 92.3, 114.7, 115.1, 126.8, 139.3, 140.2, 153.4, 154.4, 
156.1, 158.2, 163.9 and 169.8; m/z (ES+) 588.5 (M+ + 23, 100%). 
This residue with aqueous hydrogen chloride (1 M, 1.5 mL) as 
before, after chromatography (CH2Cl2 to 20% MeOH/CH2Cl2) gave 
the title compound 49 as a white solid (80 mg, 60 %), Rf 0.58 (20% 
MeOH/CH2Cl2), m.p. 143-146 °C (Found: M+ + H, 526.2532. 
C24H32O5N9 requires M, 526.2521)ν δH (500 MHz, DMSO-d6) 1.28 
(6 H, t, J 7.1, 2  NCH2CH3), 1.60 (3 H, d, J 6.9, 5-CHCH3), 2.39 
(3 H, s, 7-CH3), 2.77 (1.2 H, d, J 4.5 Hz, NHCH3), 2.78 (1.8 H, d, J 
4.4 Hz, NHCH3), 3.62 (4 H, q, J 7.1 Hz, 2  NCH2CH3), 4.21 (1 H, 
s, 3-H), 4.38 (1 H, s, 4-H), 4.66 (1 H, m, 2-H), 5.51 (1 H, m, 5-
CHCH3), 5.64 (1 H, d, J 6.0 Hz, 2-OH), 5.81 (1 H, s, 3-OH), 6.04 
(1 H, d, J 7.6, 1-H), 6.95 (1 H, s, 6-H), 8.10 (1 H, d, J 6.9 Hz, 6-
NH), 8.35 (1 H, s, 2-H), 8.53 (1 H, s, 8-H), 8.95 (0.4 H, q, J 4.5 Hz, 
NHCH3) and 8.97 (0.6 H, q, J 4.4 Hz, NHCH3); m/z (ES+) 526 (M+ 
+ 1, 100 %). 
 
1,3-Dihydroxy-4-iodo-2-nitrobenzene (55)24 
N-Iodosuccinimide (3.16 g, 12.9 mmol) was added slowly to the 
nitroresorcinol 52 (2.00 g, 12.9 mmol) in trifluoroacetic acid (50 mL, 
0.65 mol) at 0 °C and the reaction mixture was stirred at rt for 16 h, 
then poured onto ice water (30 mL). The mixture was extracted with 
toluene (3  10 mL) and the organic extracts were washed with 
saturated sodium bisulphite, dried (MgSO4) and concentrated under 
reduced pressure to give the title compound 55 (3.60 g, 100 %) as an 
orange solid, Rf 0.57 (20% EtOAc/light petroleum), m.p. 140 - 148 
°C; (Found: M+  H, 279.9112. C6H3NO4I requires M, 279.9112); δH 
(300 MHz, DMSO-d6) 6.43 (1 H, d, J 9.0 Hz, 6-H), 7.63 (1 H, d, J 
9.0 Hz, 5-H), 10.50 (1 H, br. s, 1-OH) and 11.01 (1 H, br. s, 3-OH); 
m/z (ES) 280 (M+  1, 100 %). 
 
1-Iodo-2,4-bis(methoxymethoxy)-3-nitrobenzene (56)24 
N,N-Di-isopropylethylamine (16.0 mL, 0.092 mol) and chloromethyl 
methyl ether (6.51 mL, 0.086 mol) were added sequentially at 0 °C 
to the resorcinol 55 (8.60 g, 0.031 mol) in N,N-dimethylformamide 
(100 mL) and the reaction mixture stirred at rt for 1.5 h. Brine (250 
mL) was added and the mixture was extracted with ether (3  250 
mL). The organic extracts were washed with aqueous sodium 
hydroxide (2 M, 3  200 mL), dried (MgSO4) and concentrated 
under reduced pressure to give the title compound 56 (10.9 g, 96%) 
as a yellow solid, Rf 0.37 (20 % EtOAc/light petroleum), m.p. 82 - 
84 °Cν δH (300 MHz, CDCl3) 3.41 and 3.47 (each 3 H, s, OCH3), 
5.06 and 5.15 (each 2 H, s, CH2), 6.82 (1 H, d, J 9.0 Hz, 5-H) and 
7.72 (1 H, d, J 9.0 Hz, 6-H)ν δC (100 MHz, CDCl3) 56.8, 58.1, 82.2, 
95.2, 101.0, 113.9, 138.3, 140.5, 149.6 and 149.7; m/z (ES+) 391.8 
(M+ + 23, 100 %). 
 
Methyl 2-hydroxy-4-methoxymethoxy-3-nitrobenzoate (57)24 
1,3,5,7-Tetramethyl-2,4,8-trioxa-6-phenyl-6-phospha-adamantane 
(79 mg, 0.27 mmol), palladium(II) acetate (61 mg, 0.27 mmol) and 
caesium carbonate (264 mg, 0.81 mmol) were added to the iodide 56 
(200 mg, 0.542 mmol) in methanol (3.6 mL) and the reaction 
mixture de-gassed, then stirred at 60 °C under an atmosphere of 
carbon monoxide for 16 h. Saturated aqueous ammonium chloride (5 
mL) was added and the mixture extracted with ethyl acetate (3  5 
mL). The organic extracts were dried (MgSO4) and concentrated 
under reduced pressure. Chromatography of the residue (10% 
EtOAc/light petroleum) gave the title compound 57 (130 mg, 94 %) 
as a white solid, Rf 0.2 (20 % EtOAc/light petroleum), mp 124 - 125 
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°C; (Found: M+ - H, 256.0464. C10H10NO7 requires M, 256.0452);  
δH (300 MHz, CDCl3) 3.42 (3 H, s, CH2OCH3), 3.90 (3 H, s, 
CO2CH3), 5.22 (2 H, s, CH2), 6.71 (1 H, d, J 9.0 Hz, 5-H), 7.81 (1 H, 
d, J 9.0 Hz, 6-H) and 11.32 (1 H, s, OH); δC (100 MHz, CDCl3) 
52.8, 56.9, 94.8, 105.8, 107.6, 131.5, 132.4, 154.0, 154.5 and 169.4; 
m/z (ES) 256 (M+ 1, 100 %). 
 
Methyl 5-bromo-2,4-dihydroxy-3-nitrobenzoate (58) 
Bromine (0.22 mL, 0.0043 mol) was added dropwise to the ester 57 
(1.09 g, 4.24 mmol) in chloroform (50 mL) and the reaction mixture 
stirred at rt for 48 h. The mixture was then washed with saturated 
aqueous sodium bisulphite (50 mL) and water (2  50 mL) then 
dried (MgSO4) and concentrated under reduced pressure. Re-
crystallisation of the residue from light petroleum/ethyl acetate gave 
the title compound 58 (0.99 g, 83 %) as a yellow crystalline solid, Rf 
0.23 (20 % EtOAc/light petroleum); m.p. 137 °C (Found: C, 33.09; 
H, 1.61; N, 4.81; Br, 27.21. C8H5NO6Br requires C, 32.90; H, 2.07; 
N, 4.80; Br. 27.36: Found: M+  H, 289.9297. C8H5NO679Br requires 
M, 289.9305); Ȟmax/cm-1 3080, 2957,1670, 1584, 1533, 1436, 1339, 
1253, 1138, 966, 895, 818, 793 and 775ν δH (300 MHz, CDCl3) 3.93 
(3 H, s, CO2CH3), 8.20 (1 H, s, 6-H), 11.37 (1 H, s, 2-OH) and 12.64 
(1 H, s, 4-OH)ν δC (100 MHz, CDCl3) 53.3, 101.0, 106.6, 126.1, 
139.2, 157.1, 158.9 and 169.0; m/z (ES) 292 (M+ 1, 70%), 290 
(M+ 1, 63), 260 (100) and 258 (98). 
 
Methyl 3-amino-5-bromo-2,4-dihydroxybenzoate (59) 
Concentrated acetic acid (0.8 mL) and zinc (67 mg, 1.02 mmol) were 
added sequentially to the nitro compound 58 (50.0 mg, 0.171 mmol) 
in methanol (3.3 mL) and the resulting mixture was stirred at rt for 2 
min. After filtering through a plug of silica, the filtrate was diluted 
with water (5 mL) and brine (5 mL) then extracted with ethyl acetate 
(3  10 mL). The organic extracts were washed with saturated 
aqueous sodium bicarbonate (5 mL) and water (5 mL), dried 
(MgSO4) and concentrated under reduced pressure. The residue was 
chromatographed (10% EtOAc in light petroleum) to give the title 
compound 59 (44 mg, 98 %) as a white solid, Rf 0.37 (30 % 
EtOAc/light petroleum), m.p. 160 °C (Found: M+  H, 261.9530. 
C8H7NO481Br requires M, 261.9543)ν Ȟmax/cm-1 3181, 2949, 2916, 
2848, 1666, 1623, 1548, 1522, 1430, 1340, 1256, 1200, 1150, 1089, 
1015, 981, 890, 796 and 778ν δH (400 MHz, CDCl3) 3.85 (3 H, s, 
CO2CH3), 7.38 (1 H, s, 6-H) and 10.79 (1 H, s, OH); m/z (ES) 262 
(M+  1, 98%), 260 (M+ 1, 100), 230 (15) and 228 (13). 
 
Methyl 7-bromo-2-dimethylamino-4-hydroxybenz[d]oxazole-5-
carboxylate (60) 
Triethylamine (80 ȝL, 0.574 mmol) and 
dichloromethylene(dimethyl)ammonium chloride (28 mg, 0.172 
mmol) were added to the aminophenol 59 (30 mg, 0.114 mmol) in 
dichloromethane (2 mL) and the reaction mixture was heated under 
reflux for 2 h. After cooling to rt, the mixture was washed with 
saturated aqueous sodium bicarbonate (10 mL) and extracted with 
dichloromethane (3  10 mL). The organic extracts were dried 
(MgSO4) and concentrated under reduced pressure. The residue was 
chromatographed (10% EtOAc in light petroleum) to give the title 
compound 60 (20 mg, 56 %) as a white solid, Rf 0.17 (30 % 
EtOAc/light petroleum), m.p. 95 – 97 °C (Found: M+ + H, 314.9972. 
C11H12N2O479Br requires M, 314.9975)ν Ȟmax/cm-1 3224, 2952, 1651, 
1435, 1311, 1220, 1160, 1078, 1014, 978, 887, 788 and 731; δH (400 
MHz, CDCl3) 3.17 (6 H, s, 2  NCH3), 3.89 (3 H, s, CO2CH3), 7.62 
(1 H, s, 6-H) and 10.95 (1 H, s, OH)ν δC (100 MHz, CDCl3) 37.9, 
52.5, 91.2, 109.7, 124.5, 132.9, 151.0, 151.3, 162.2 and 170.1; m/z 
(ES) 315 (M+  1,100%) and 313 (M+  1, 83). 
 
Methyl-7-bromo-2-dimethylamino-4-(3-methylisoxazol-5 
ylmethoxy)benz[d]oxazole-5-carboxylate (61) 
5-Hydroxymethyl-3-methylisoxazole (43 mg, 0.38 mmol) and 
triphenylphosphine (125 mg, 0.477 mmol) were added to the phenol 
60 (100 mg, 0.317 mmol) in tetrahydrofuran (10 mL) and the 
mixture cooled to 0 oC. Di-isopropyl azodicarboxylate (93.5 ȝL, 
0.476 mmol) in tetrahydrofuran (5 mL) was added dropwise and the 
reaction mixture was stirred at rt for 16 h. The reaction mixture was 
concentrated under reduced pressure and the residue was 
chromatographed (10% EtOAc in light petroleum) to give the title 
compound 61 as a white solid (130 mg, 99 %), Rf 0.33 (50 % 
EtOAc/light petroleum), m.p. 106 - 110 °C (Found: M+ + H, 
410.0347. C16H17N3O579Br requires M, 410.0346); Ȟmax/cm-1 2945, 
1696, 1651, 1618, 1428, 1404, 1380, 1339, 1303, 1251, 1189, 1165, 
1027, 978, 897, 885, 857, 798, 781 and 716ν δH (400 MHz, CDCl3) 
2.30 (3 H, s, 3-CH3), 3.24 (6 H, s, 2  NCH3), 3.89 (3 H, s, 
CO2CH3), 5.73 (2 H, s, CH2), 6.26 (1 H, s, 4-H) and 7.64 (1 H, s, 6-
H)ν δC (100 MHz, CDCl3) 11.5, 37.7, 52.3, 65.2, 94.3, 103.9, 119.9, 
126.0, 135.8, 145.8, 150.6, 159.8, 161.7, 165.7 and 168.4; m/z (ES+) 
434 (M+ + 23, 63%) and 432 (M+ + 23, 76), 412 (M+ + 1, 90) and 
410 (M+ + 1, 100). 
 
7-Bromo-2-dimethylamino-5-hydroxymethyl-4-(3-
methylisoxazol-5 ylmethoxy)benz[d]oxazole (62) 
A mixture of sodium borohydride (46 mg, 1.22 mmol) and calcium 
chloride (54 mg, 0.487 mmol) in tetrahydrofuran (2 mL) was stirred 
at rt for 2 h before adding the ester 61 (100 mg, 0.244 mmol). The 
resulting mixture was stirred at rt for 48 h and the pH was adjusted 
to 7 using aqueous hydrogen chloride (1 M). The mixture was 
concentrated under reduced pressure and the residue was 
chromatographed (40% EtOAc in light petroleum) to give the title 
compound 62 as a white solid (70 mg, 75 %), Rf 0.27 (50 % 
EtOAc/light petroleum), m.p. 140 – 142 °C (Found: M+ + Na, 
404.0227. C15H16N3O4Na79Br requires M, 404.0217)ν Ȟmax/cm-1 
3352, 3139, 2934, 1649, 1616, 1593, 1432, 1377, 1271, 1248, 1226, 
1194, 1092, 1067, 1017, 960. 892, 801, 753 and 722ν δH (400 MHz, 
CDCl3) 2.04 (1 H, m, OH), 2.20 (3 H, s, 3-CH3), 3.15 (6 H, s, 2  
NCH3), 4.54-4.58 (2 H, m, 5-CH2), 5.69 (2 H, s, OCH2), 6.03 (1 H, 
s, 4-H) and 7.00 (1 H, s, 6-H)ν δC (100 MHz, CDCl3) 11.4, 37.7, 
61.4, 63.7, 93.6, 104.2, 123.2, 128.5, 134.2, 143.0, 148.1, 159.8, 
161.5 and 168.2; m/z (ES+) 406 (M+ + 23, 100%) and 404 (M+ + 23, 
92 %).  
 
N-[7-Bromo-2-dimethylamino-4-(3-methylisoxazol-5-
ylmethoxy)benz[d]oxazol-5-yl]methyl 2-
nitrobenzenesulfonamide (63)  
2-Nitrobenzene sulphonamide (222 mg, 1.10 mmol) and 
triphenylphosphine (72 mg, 0.275 mmol) were added to the alcohol 
62 (70 mg, 0.183 mmol) in dichloromethane (14 mL) and the 
mixture cooled to 0 oC. Di-isopropyl azodicarboxylate (54.1 ȝL, 
0.275 mmol) in dichloromethane (3.5 mL) was added dropwise and 
the reaction mixture was stirred at rt for 16 h. After concentration 
under reduced pressure, chromatography of the residue (10% to 30% 
EtOAc/light petroleum) gave the title compound 63 as a pale yellow 
oil (90 mg, 87 %), Rf 0.2 (50 % EtOAc/light petroleum) (Found: M+ 
+ 1, 566.0344, C21H2179BrN5O7S requires M, 566.0340)ν Ȟmax/cm-1 
3364, 3265, 2931, 1655, 1617, 1588, 1537, 1483, 1433, 1359, 1345, 
1268, 1246, 1168, 1123, 1099, 1035, 897, 859, 782, 738 and 720ν δH 
(500 MHz, CDCl3) 2.20 (3 H, s, 3-CH3), 3.10 (6 H, s, 2  NCH3), 
4.18 (2 H, d, J 6.5 Hz, 5-CH2), 5.60 (2 H, s, OCH2), 5.99 (1 H, t, J 
6.5 Hz, NH), 6.04 (1 H, s, 4-H), 6.75 (1 H, s, 6-H), 7.51 and 7.54 
(each 1 H, m, 4-H, 5-H), 7.68 (1 H, m, 6-H) and 7.92 (1 H, m, 
3- H)ν δC (125 MHz, CDCl3) 11.4, 37.7, 44.2, 63.6, 92.9, 104.4, 
122.8, 124.1, 125.2, 131.1, 132.5, 133.1, 133.7, 134.3, 143.1, 147.4, 
148.3, 159.8, 161.4 and 167.7; m/z (ES) 566 (M+  1, 100%) and 
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564 (M+  1, 99). 
 
5-Aminomethyl-7-bromo-2-dimethylamino-4-(3-methylisoxazol-
5- ylmethoxy)benz[d]oxazole (51) 
Thiophenol (49 ȝL, 0.477 mmol) and potassium carbonate (88 mg, 
0.636 mmol) were added to the sulfonamide 63 (90 mg, 0.16 mmol) 
in acetonitrile (10 mL) and the reaction mixture was stirred at rt for 
16 h. After concentration under reduced pressure, chromatography of 
the residue (1% MeOH/CH2Cl2 with a drop of Et3N) gave the title 
compound 51 as a white solid (60 mg, 98 %), Rf 0.13 (10 % 
MeOH/EtOAc), m.p. 212 - 218 °C (Found: M+ + 1, 381.0553, 
C15H18N4O379Br requires M, 381.0557); Ȟmax/cm-1 3386, 2926, 1655, 
1610, 1593, 1428, 1377, 1273, 1252, 1227, 1194, 1098, 1073, 1021, 
969, 893, 846 and 724ν δH (500 MHz, CDCl3) 1.94 (2 H, br. s, NH2), 
2.19 (3 H, s, 3-CH3), 3.14 (6 H, s, 2  NCH3), 3.70 (2 H, s, 5-CH2), 
5.67 (2 H, s, OCH2), 6.03 (1 H, s, 4- H) and 6.92 (1 H, s, 6-H)ν δC 
(125 MHz, CDCl3) 11.4, 37.7, 42.1, 63.7, 93.4, 104.1, 123.0, 130.6, 
134.3, 143.0, 147.5, 159.7, 161.5 and 168.4; m/z (ES+) 383 (M+ + 1, 
100%), 381 (M+ + 1, 96), 366 (85) and 364 (80). 
 
1-{6-[7-Bromo-2-dimethylamino-4-(3-methylisoxazol-5-
ylmethoxy)benz[d]oxazol-5-ylmethylamino]-9H-purin-9-yl}-2,3-
O-isopropylidene-1-deoxy-N-methyl--D-ribofuranuronamide 
(64) 
Triethylamine (44 ȝL, 0.315 mmol) and purine 4 (56 mg, 0.157 
mmol) were added to the amine 51 (60 mg, 0.157 mmol) in ethanol 
(2.5 mL) and the reaction mixture was heated under reflux for 18 h. 
After concentration under reduced pressure, chromatography of the 
residue (EtOAc to 10% MeOH/EtOAc) gave the title compound 64 
as a transparent solid (100 mg, 91%), Rf 0.17 (EtOAc), m.p. 105 – 
110 °C (Found: M+ + 1, 698.1662. C29H33N9O779Br requires M, 
698.1681)ν Ȟmax/cm-1 3288, 3082, 2928, 2805, 2358, 1653, 1612, 
1535, 1476, 1429, 1406, 1377, 1328, 1273, 1211, 1156, 1088, 981, 
899, 869, 850, 796 and 726ν δH (400 MHz, CDCl3) 1.30 and 1.55 
(each 3 H, s, CH3), 2.18 (3 H, s, 3-CH3), 2.55 (3 H, d, J 5.0 Hz, 
NHCH3), 3.14 (6 H, s, 2  NCH3), 4.64 (1 H, s, 4-H), 4.74 (2 H, br. 
s, 5-CH2), 5.26 (2 H, m, 2-H and 3-H), 5.70 (2 H, d, J 1.0 Hz, 5-
CH2), 5.95 (1 H, d, J 2.0 Hz, 1-H), 6.05 (1 H, s, 4-H), 6.35 (1 H, 
br. s, 6-NH), 7.05 (1 H, s, 6-H), 7.27 (1 H, br. s, NHCH3), 7.68 (1 
H, s, 2-H) and 8.27 (1 H, br. s, 8-H)ν δC (100 MHz, CDCl3) 11.4, 
14.2, 21.1, 25.1, 25.6, 27.1, 37.7, 60.4, 63.8, 82.5, 83.7, 85.7, 92.1, 
93.5, 104.2, 114.5, 123.6, 134.3, 139.2, 143.3, 148.0, 153.2, 154.8, 
159.7, 161.5, 168.2 and 169.5; m/z (ES+) 700 (M+ + 1, 100%) and 
698 (M+ + 1, 93). 
 
1-{6-[7-Bromo-2-dimethylamino-4-(3-methylisoxazol-5-
ylmethoxy)benz[d]oxazol-5-ylmethylamino]-9H-purin-9-yl}-1-
deoxy-N-methyl--D-ribofuranuronamide (50). 
A solution of the acetonide 64 (50.0 mg, 0.0716 mmol) in aqueous 
formic acid (80%, 0.5 mL) was stirred at rt for 16 h then 
concentrated under reduced pressure. Chromatography of the residue 
(1% MeOH/EtOAc) and recrystallisation from ethyl acetate gave the 
title compound 50 (40 mg, 85 %) as a white solid, Rf 0.37 (10% 
MeOH/EtOAc), m.p. 235 - 237 °C (Found: M+ + 1, 658.1373. 
C26H29N9O779Br requires M, 658.1368)ν Ȟmax/cm-1 3198, 2939, 2360, 
1666, 1591, 1625, 1484, 1432, 1405, 1385, 1360, 1339, 1299, 1260, 
1189, 1145, 1093, 1065, 1026, 961, 894, 857, 794, 756 724 and 638; 
δH (400 MHz, DMSO-d6) 1.96 (3 H, s, 3-CH3), 2.47 (3 H, d, J 4.5 
Hz, NHCH3), 2.91 (6 H, s, 2  NCH3), 3.91 (1 H, m, 3-H), 4.08 (1 
H, s, 4-H), 4.33 (1 H, m, 2-H), 4.44 (2 H, br. s, 5-CH2), 5.34 (1 H, 
d, J 6.0 Hz, 2-OH), 5.49 (2 H, s, 5-CH2), 5.52 (1 H, d, J 4.3 Hz, 
3-OH), 5.74 (1 H, d, J 7.3 Hz, 1-H), 6.21 (1 H, s, 4-H), 6.74 (1 H, 
s, 6-H), 8.03 (1 H, s, 2-H), 8.16 (1 H, br. s, 6-NH), 8.21 (1 H, s, 8-
H), 8.66 (1 H, q, J 4.5 Hz, NHCH3)ν δC (100 MHz, DMSO-d6) 10.9, 
25.3, 37.3, 60.1, 63.2, 72.1, 73.0, 84.6, 87.8, 92.8, 104.6, 120.0, 
121.0, 127.4, 134.3, 140.8, 142.2, 146.5, 148.2, 152.5, 154.4, 159.6, 
161.2, 167.8 and 169.8; m/z (ES+) 682 (M+ + 23, 100%), 680 (M+ + 
23, 75), 660 (M+ + 1, 49) and 658 (M+ + 1, 58).  
 
X-Ray crystal data 
5,7-Dimethyl-2-dimethylamino-oxazolo[4,5-b]pyridine 4-oxide (14): 
C10H13NO2; unit cell parameters: a 16.652(2), b 6.8992(9), c 
18.610(3); Pbca, CCDC number 1442372. 
        2-Dimethylamino-7-hydroxymethyl-5-methyloxazolo[4,5-
b]pyridine (15): C10H13N3O2; unit cell parameters: a 7.6207(7), b 
12.3266(12), c 11.1367(11); P21, CCDC number 1442373. 
        7-Bromo-2-dimethylamino-5-hydroxymethyl-4-(3-
methylisoxazol-5 ylmethoxy)benz[d]oxazole (62): C15H16BrN3O4; 
unit cell parameters: a 27.5444(14), b 4.0773(4), c 26.9996(14); 
Pca21, CCDC number 1442374. 
 
 
Acknowledgements 
We thank Muscagen Ltd., for studentships (to E. B. and S. S.) and 
for aditional support (to A. T. L. L.).  
 
Notes and references 
 
aCardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff 
University, Redwood Building, King Edward VII Avenue, Cardiff, CF10 
3NB, UK 
bThe School of Chemistry, The University of Manchester, Manchester, M13 
9PL, UK 
c
 Muscagen Limited, 10, North Road, Cardiff, CF10 3DY 
†Deceased October 2011.  
 
Electronic Supplementary Information (ESI) available: [details of any 
supplementary information available should be included here]. See 
DOI: 10.1039/b000000x/ 
 
1. (a) V. E. Laubach, B. A. French and M. D. Okusa, Expert. Opin. 
Ther. Targets, 2011, 15, 103; (b) P. Fishman, S. Bar-Yehuda, B. 
T. Liang and K. A. Jacobson, Drug Discov. Today, 2012, 17, 
359; (c) V. J. McIntosh and R. D. Lasley, J. Cardiovasc. 
Pharmacol. Therapeutics, 2012, 17, 21; (d) P. G. Baraldi, D. 
Preti, P. A. Borea and K. Varani, J. Med. Chem., 2012, 55, 5676; 
(e) A. M. Almerico, M. Tutone, L. Pantano and A. Lauria, J. 
Mol. Graphics Modell., 2013, 42, 60.  
2. P. A. Borea, K. Varani, F. Vincenzi, P. G. Baraldi, M. A Tabrizi, 
S. Merghi and S. Gessi, Pharmacol. Rev., 2015, 67, 74. 
3.  C. Gallo-Rodriguez, X.-d. Ji, N. Melman, B. D. Siegman, L. H. 
Sanders, J. Orlina, B. Fischer, Q. Pu, M. E. Olah, P. J. M. van 
Galen, G. L. Stiles and K. A. Jacobson, J. Med. Chem., 1994, 37, 
636. 
4. (a) P. G. Baraldi, B. Cacciari, G. Spalluto, X.-d. Ji, M. E. Olah, 
G. Stiles, S. Dionisotti, C. Zocchi, E. Ongini and K. A. Jacobson, 
J. Med. Chem., 1996, 39, 802; (b) M. P. DeNinno, H. 
Masamune, L. K. Chennard, K. J. DiRico, C. Eller, J. B. Etienne, 
J. E. Tichner, S. P. Kennedy, D. R. Knight, J. Kong, J. J. 
Oleynek, W. R. Tracey and R. J. Hill, J. Med. Chem., 2003, 46, 
353; (c) S. M. Devine, A. Gregg, H. Figler, K. McIntosh, V. 
Urmaliya, J. Linden, C. W. Pouton, P. J. White, S. E. Bottle, P. J. 
Scammells, Bioorg. Med. Chem., 2010, 18, 3078. 
5. R. H. Davies, C. McGuigan, unpublished observations. 
6. R. H. Davies, unpublished observations. 
7. R. A. Olsson, S. Kusachi, R. D. Thompson, D. Ukena, W. 
Padgett and J. W. Daly, J. Med. Chem., 1986, 29, 1683. 
 ARTICLE 
 
8. (a) Y. Wang, M.-C. Liu, T.-S. Lin and A. C. Sartorelli, J. Med. 
Chem., 1992, 35, 3667; (b) E. Blanz and F. French, Cancer Res., 
1968, 28, 2419; (c) K. C. Agrawal, A. J. Lin, B. A. Booth, J. R. 
Wheaton and A. C. Sartorelli, J. Med. Chem., 1974, 17, 631; (d) 
V. J. Traynelis and P. L. Pacini, J. Am. Chem. Soc., 1964, 86, 
4917. 
9. (a) D. Chapman and J. Hurst, J. Chem. Soc., Perkin Trans. I, 
1980, 2398; (b) S. Furukawa, Yakugaku Zasshi, 1956, 76, 900. 
10. R. C. De Selms, J. Org. Chem., 1968, 33, 478.  
11. (a) R. Sathunuru, U. N. Rao and E. Biehl, Arkivoc, 2003, 15, 
124; (b) N. C. Ganguly, M. Datta, P. De and R. Chakravarty, 
Synth. Commun., 2003, 33, 647; R. Sathunuru and E. Biehl, 
Arkivoc, 2004, 14, 89.  
12. (a) M. Katada, Yakugagu Zasshi, 1947, 67, 51; (b) S. Furukawa, 
Pharm. Bull., 1955, 3, 413. 
13. C. Fontenas, E. Bejan, H. A. Haddou and G. G. A. Balavoine, 
Synth. Commun., 1995, 25, 629. 
14. P. Månsson, Tetrahedron Lett., 1982, 23, 1845. 
15. T. Fukuyama, C.-K. Jow and M. Cheung, Tetrahedron Lett., 
1995, 36, 6373. 
16. (a) Y. Sato, M. Yamada, S. Yoshida, T. Soneda, M. Ishikawa, T. 
Nizato, K. Suzuki and F. Konno, J. Med. Chem., 1998, 41, 3015; 
(b) S. Yoshida, S. Shiokawa, K. Kawano, T. Ito, H. Marakami, 
H. Suzuki and Y. Sato, J. Med. Chem., 2005, 48, 7075. 
17. (a) K. Gunnar and J. Sandström, Acta Chem. Scand., 1969, 23, 
2888; (b) I. J. Turchi and M. J. S. Dewar, Chem. Rev., 1975, 75, 
389. 
18. T. Fukuyama, M. Cheung and T. Kan, Synlett, 1999, 1301. 
19. T. Kan and T. Fukuyama, Chem. Commun., 2004, 353. 
20. (a) G. Liu, D. A. Cogan and J. A. Ellman, J. Am. Chem. Soc., 
1997, 119, 9913; (b) D. A. Cogan, G. Liu, K. Kim, B. J. Backes 
and J. A. Ellman, J. Am. Chem. Soc., 1998, 120, 8011. 
21. J. A. Ellman, T. D. Owens and T. P. Tang, Acc. Chem. Res., 
2002, 35, 984. 
22. (a) K. C. Nicolaou, A. Li and D. J. Edmonds, Angew. Chem. Int. 
Edn., 2006, 45, 7086; (b) K. C. Nicolaou, A. Li, D. J. Edmonds, 
G. S. Tria and S. P. Ellery, J. Am. Chem. Soc., 2009, 131, 16905. 
23. (a) S. R. Crabtree, W. L. A. Chu and L. N. Mander, Synlett, 
1990, 169; L. N. Mander and S. P. Sethi, Tetrahedron Lett., 
1983, 24, 5425; (c) S. R. Crabtree, L. N. Mander and S. P. Sethi, 
Org. Synth., 1991, 70, 256. 
24. J. Wang, V. Lee and H. O. Sintim, Chem. Eur. J., 2009, 15, 
2747. 
25. J. McNulty, J. J. Nair and A. Capretta, Tetrahedron Lett., 2009, 
50, 4087. 
26. (a) J. Liu, B. Liang, D. Shu, Y. Hu, Z. Yang and A. Lei, 
Tetrahedron, 2008, 64, 9581; C. F. J. Barnard, Org. Process Res. 
Devel., 2008, 12, 566. 
27. (a) S. Narasimban, K. G. Prasad and S. Madhavan, Synth. 
Comm., 1995, 25, 1689; (b) J. W. Lampe, Y.-L. Chou, R. G. 
Hanna, S. V. DiMeo, P. W. Erhardt, A. A. Hegedorn, III, W. R. 
Ingebretson and E. Cantor, J. Med. Chem., 1993, 36, 1041. 
